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Abstract 
 
Relaxin-like factor (RLF), also known as Leydig insulin-like peptide (Ley-I-L) (Adham, 
et al., 1993) or Insulin 3 (INSL3) (Nef and Parada, 1999), is a newly characterized 
member of the insulin peptide family. Amino acid sequence homology revealed that RLF 
is more closely related to relaxin than any other insulin-like hormones. Though relaxin 
and RLF are very similar in structure and size, they are different in sites of expression 
and function. RLF is expressed in Leydig cells of foetal and adult testes and in theca and 
luteal cells of the postnatal ovary at lower levels, while relaxin is predominantly found in 
the ovary. RLF deletion in male mice showed impaired development of the gubernaculum 
ligament which resulted in undescended testes and infertility, a condition known as 
cryptorchidism. By contrast, relaxin is generally associated with female reproductive 
physiology.  The RLF gene had not been sequenced in the rat prior to the commencement 
of this project, despite the fact that the RLF gene had been characterized in several 
species including human, pig and mouse. 
 
Sequencing of a genomic clone encoding the mouse gene for the relaxin-like factor (RLF) 
indicated that it was located within the 3' end of the mouse JAK3 gene (Koskimies, et al, 
1997).  JAK3 gene is expressed predominantly in lymphoid tissues. The published mouse 
sequence for exon 23 of the JAK3 gene in fact comprises two exons, 23A and 23B, 
separated by an additional novel intron of 2.2 kb.  It is within this novel 2.2 kb intron that 
the promoter and exon 1 of mouse RLF gene are located. Further more exon 2 is found to 
be syngeneic to exon 23b of mouse JAK3 gene (Koskimies, et al, 1997).    
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The receptor for RLF is a G protein-coupled, seven transmembrane domain protein with a 
uniquely large leucine-rich ectodomain for ligand interaction. At present, there are eight 
different leucine-rich repeat-containing G protein-coupled receptors (LGRs) that have 
been characterised, with LGR8 being the receptor for RLF.  In human, LGR8 is highly 
expressed in the testes, and at lower levels in the brain, kidney, muscle, thyroid, 
peripheral blood cells, uterus and bone marrow. Due to the localisation of its receptor, 
RLF was initially proposed to be an autocrine factor, with its major function in the 
Leydig cells. However, recent studies suggest that it is a circulating hormone in both 
genders with higher levels in post-pubertal males than in children or post-pubertal 
females. 
 
The main aim of this thesis was firstly to amplify and sequence the rat RLF gene to 
determine the structure and organisation of the gene.  Secondly to compare the structural 
organisation of the rat JAK3/RLF promoter region with that of the mouse and human, 
using bioinformatic databases. Thirdly to further investigate the signalling pathways for 
RLF receptor, in particular the NFκB pathway 
 
Sets of primers were designed by aligning the sequences of RLF genomic DNA from the 
three known species mouse, pig and human.  Polymerase chain reaction (PCR) method 
was adopted to amplify the rat RLF gene from rat liver.  
 
The complete RLF gene from rat was obtained and characterized by nucleotide 
sequencing.  The encoded amino acid sequence of the rat hormone was compared with 
the RLF amino acid sequences of mouse, pig and human.  It was observed that the rat 
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amino acid sequence has 94% homology to that of the mouse and lesser homology to pig 
and human.  
The homology between rat and mouse in the JAK3/RLF region revealed 84.4 % 
similarity over 1262 bp of DNA sequence, observing that unlike the mouse, the rat RLF 
promoter is separated from the JAK3 gene by around 700-1000 bp.  Similarly in humans, 
the RLF gene is located around 4 kb downstream from JAK3. 
To investigate RLF signaling an expression vector for LGR8 (RLF receptor) was co-
transfected with signalling pathway reporter genes into mammalian cells.  The cells were 
then incubated with RLF and assayed for pathway activation by quantifying the amount 
of reporter protein present in cell medium. 
 
Protein kinase A (PKA) was the only pathway with major reporter induction when 
compared to cells without RLF treatment. The experimental work showed that the RLF 
receptor is able to signal through the PKA pathway and no inhibitory effects were 
observed with the NFκB reporter gene.
 1 
The Characterization of Rat Relaxin-like Factor Gene 
 
CHAPTER 1 
1.1 General introduction 
 
1.1.1 Relaxin and insulin peptide family 
 
Relaxin was first discovered in the 1920s by Hisaw (Hisaw, 1926). Years later, a crude 
extract was obtained from sow corpora lutea and the active ingredient was shown to have 
the characteristics of peptide hormones and displayed the same relaxation effect on the 
interpubic ligament (Fevold, et al., 1930). The active component was then given the name 
relaxin. 
 
Relaxin is one of the regulatory peptides of the insulin super family, which includes 
insulin, other insulin-like hormones, and growth factors in vertebrates and invertebrates 
(Pertseva, et al., 2006). Relaxin and insulin, discovered only years apart, were the two 
peptides which established the notion of the insulin superfamily. The insulin super family 
consists of peptides with highly related structures, but low sequence similarity (Wilkinson, 
et al., 2005). The group represents relaxin 1, 2 and 3, insulin-like growth factor I and II 
(IGF II and I) whose biological functions have diverged (Hombach-Klonisch, et al., 1999) 
and the insulin like peptides INSL3, INSL4, INSL5 and INSL6. They play a significant 
role in regulating growth and development in many different tissues. These peptides have a 
structural and functional similarity sharing of a common evolutionary origin (Pertseva, et 
al., 2006).  
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Relaxin is a pleiotropic endocrine and paracrine factor capable of regulating many cell 
processes, such as growth, differentiation, apoptosis and metabolism (Ivell and Einspanier, 
2002).  
 
Insulin is a polypeptide hormone secreted by the islets of Langerhans presence in the 
pancreas and functions in the regulation of the metabolism of carbohydrates and fats, 
especially the conversion of glucose to glycogen, which lowers the blood glucose level 
(Banting, et al., 1991). 
 
In the last decade, interest in relaxin and the insulin-like peptides has continued to grow. In 
addition to its regulatory function in the reproductive system, relaxin has a variety of roles 
in the cardiovascular, renal, central nervous and other systems (Ivell and Einspanier, 2002). 
In addition, additional new hormones of the relaxin family (relaxin 3, relaxin-like peptides) 
have been discovered. Recently, the receptors for particular relaxin family hormones have 
been elucidated (Ivell and Einspanier, 2002).    
 
1.1.2 The RLF peptide and gene 
The relaxin-like factor gene (RLF) is also known as Leydig insulin-like peptide (Ley-I-L) 
because of its discovery in Leydig cells (Adham, et al., 1993). Recently RLF is widely 
known as insulin3 peptide (INSL3) (Nef and Parada, 1999). 
RLF is a novel member of the insulin / IGF / relaxin superfamily. The RLF is a circulating 
hormone that is synthesised in the gonads of mammals and released into the bloodstream 
(Bullesbach and Schwabe, 1999a). RLF was originally isolated from a porcine testis cDNA 
library by differential screening (Adham, et al., 1993). The deduced precursor protein was 
found to have homology with members of the insulin related hormone super family, as it is 
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composed of a signal peptide, B-chain, connecting C-peptide and A-chain. The mature 
porcine amino acid sequence (A and B chains) has 34% homology to porcine relaxin and 
30% homology to porcine insulin. However, the secondary structure of RLF, specifically 
the position of disulfide bond forming-cycteine suggests that the hormone has a tertiary 
structure very similar to relaxin. Also, due to the existence of a number of conserved 
amino acids of the A and B chain at the N and C terminal regions of RLF, it is suggested 
that the in vivo processing of the hormone is more similar to relaxin and insulin as 
compared to any other members within the insulin related hormone super family (Adham, 
et. al., 1993). 
 
 The cDNA sequence for RLF has subsequently been determined from a number of species 
including human (Burkhardt, et al., 1994a), pig (Burkhardt, et al., 1994a), mouse (Pusch, et 
al., 1996), sheep (Roche, et al., 1996), Marmosert monkey (Zarreh-Hoshyari-Khan, et al., 
1999) and cattle (Bathgate, et al., 1996). The deduced amino acid sequence for RLF is 
relatively well conserved between these species, with human RLF having 83%, 76% and 
75% identity to pig, sheep and mouse respectively.  The structural organization of the RLF 
gene for human and pig is also known (Burkhardt, et al., 1994a). 
The RLF gene consists of two exons and one intron, with a similar organization to the 
relaxin and insulin gene (Fig1.1). The intron interrupts the coding sequence of the C-
peptide at an equivalent position in the three genes.  However, the insulin gene is different 
to RLF and relaxin in that it contains an additional intron, which interrupts the 5’ 
untranslated sequence.  Therefore, it is highly likely that the three genes have evolved from 
a common ancestral gene by gene duplication and subsequently undergone significant 
divergence.   
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Fig. 1.1:  The RLF gene consists of two exons (exon one 175bp and exon 
    two 250bp) and one intron of 800bp.  The intron interrupts the coding 
   sequence of the C-peptide at equivalent position in the three  
 hormones RLF, relaxin and insulin.  The coding protein consists of B-
chain, connecting C-peptide and A-chain. 
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Furthermore, the three genes are located on different chromosomes.  In humans, the insulin 
gene is assigned to chromosome 11p15 (Owerbach, et al., 1980), relaxin to 9qter-q12 
(Crawford, et al., 1984) and RLF to region bp13.2-p12 of chromosome 19 (Burkhardt, et 
al., 1994a).  
 
Relaxin-like factor is synthesised as a single chain pre-pro-hormone, in which subsequent 
proteolytic digestion of the signal peptide and the connecting peptide results in the final 
mature hormone (Adham, et al., 2000). The RLF signal peptide functions as a secretion 
facilitator of the pro-hormone. On the other hand, the connecting C peptide mediates 
folding of the protein and the formation of disulfide bridges between the A and B chains in 
the biologically active hormone (Adham, et al., 2000). 
 
The tertiary structure of the active RLF hormone consists of the A chain which contains 
26-residue long and B chain that consists of 31 residue long. Furthermore, the sequence C-
G-G-P-R-W in the C terminus of the B chain seems to be essential for high affinity binding 
of RLF to its receptor.  Ninety percent (90%) or greater loss of activity has been reported 
as a result of chemical alterations of this region (Bullesbach and Schwabe, 1995; 
Bullesbach and Schwabe, 1999a). 
 
The presence of conserved amino acids in the A and B chains of relaxin and RLF, suggest 
that the structure of RLF is more closely related to relaxin than any other insulin related 
hormones (Bullesbach and Schwabe, 1995; Bullesbach and Schwabe, 1999a; Bullesbach 
and Schwabe, 2002). 
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Two independent groups have developed knock out mice for RLF (Nef and Parada, 1999; 
Zimmermann, et al., 1999). The RLF/Insulin3 (Insl3-/-) transgenic mice were made by 
deleting the RLF gene through homologous recombination (Nef and Parada, 1999; 
Zimmermann, et al., 1999). A replacement targeting vector was designed to delete the two 
exons encoding the RLF/Insl3 factor and replaced them with the neomycin 
phosphotransferase gene under the control of the phosphoglycerate kinase promoter 
(Zimmermann, et al., 1999).   The major phenotype in these mice was the lack of testicular 
descent in the male RLF/Insulin3 knock out mice (Insl3-/-) due to the failure to develop a 
specific ligament, the genitor-inguinal ligament or gubernaculums (Smith, et al., 2001). 
This phenotype suggests a role for RLF in testicular function and male fertility. 
 
1.1.3 Spatial and temporal expression of RLF RNA 
The expression of the RLF gene appears to be highly restricted in the Leydig cells of the 
testis (Ivell, 1997).  Northern blot analysis and situ hybridization in the pig indicated that 
the gene is abundantly expressed in Leydig cells of the testes (Adham, et al., 1993). In 
males, RLF regulates testicular decent during fetal life whereas in adults, it acts as a germ 
cell survival factor. Thus, it has been suggested that the RLF could play an important role 
in testicular function and in spermatogenesis (Adham, et al., 1993).   
 
High levels of RLF mRNA expression has also been described in human testes (Burkhardt, 
et al., 1994b) and immunohistochemistry has confirmed high levels of RLF protein within 
human Leydig cells (Ivell, 1997). However, it has been reported that human RLF is also 
expressed in cyclic corpora lutea of the ovary and very low levels are detected in 
trophoblasts (Tashima, et al., 1995).  
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In contrast to other species, the RLF gene in cattle is also expressed at a high level in the 
ovary, where its expression pattern in the corpus luteum of the late cycle and pregnancy is 
similar to that of relaxin in the pig (Bathgate, et al., 1999). 
 
Studies with sheep have also confirmed the expression of RLF in both the testes and ovary 
(Roche, et al., 1996).  It has also been determined which ovarian cell types express RLF by 
in situ hybridization.  High levels of RLF mRNA were detected in the theca interna and 
corpus luteum, with no detectable expression in the granulosa cell layer (Roche, et al., 
1996).  
Ruminants have an unusually high ovarian expression of RLF and undetectable relaxin 
mRNA levels in late pregnancy. Thus, it is tempting to speculate that RLF may be able to 
functionally substitute for relaxin (Roche, et al., 1996; Bathgate, et al. 1999). However, in 
a study of the sheep ovary there was no significant increase in RLF mRNA levels during 
pregnancy (Roche, et al., 1996). This demonstrates that RLF does not have the same 
temporal pattern in female reproduction as relaxin, which is up regulated during pregnancy 
(Sherwood, et al., 1993). These various studies have not found any expression of RLF in 
brain, lung, kidney, adrenal, spleen, thyroid and liver.  Thus, the fact that RLF is expressed 
in both the testis and the ovary indicates that the hormone probably has a wider biological 
role than initially suggested.  
Studies on the developmental expression of RLF in rat testis indicate that the gene is up 
regulated during puberty with levels increasing steadily until full sexual maturity (Pusch, 
et. al., 1996).  It is possible; therefore, the RLF gene is directly or indirectly regulated by 
androgens. Targeted deletion in the mice RLF gene during fetal development shows an 
inhibition of testicular descent due to malfunction of the gubernaculums in the parental 
period (Zimmermann, et al., 1999).  
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The expression of both mRNA and protein appear to be decreased in hyperplastic Leydig 
cells, whereas in the Leydig cell adenomas, large central areas of adenoma were devoid of 
RLF mRNA and protein. Only Leydig cells located at the periphery of the adenoma 
displayed expression of RLF, with full agreement between in situ hybridization and 
immunohistochemistry. It thus appears that the expression of the RLF gene and its 
products are down regulated in Leydig cell hyperplasia and adenoma, consistent with a 
concomitant dedifferentiation of these cells (Klonisch, et al., 1999). It is likely, however, 
that other male functions may also be perturbed in the adult.  
 
1.2.1 RLF gene organization within JAK3 locus 
A study using human cells unexpectedly found an alternatively spliced product, which 
comprises JAK3 and RLF mRNAs (Safford, et al., 1997). In addition, sequencing of a 
genomic clone encoding the mouse gene for RLF hinted that similar sequences were also 
present at 3’ end of the mouse JAK3 gene (Koskimies, et al, 1997). 
 
1.2.2 Janus tyrosine kinase 3 (JAK3) 
Janus tyrosine kinase 3 (JAK3) is one of several key regulatory enzymes in B-cell 
precursors which is highly conserved between multiple species (Wood, et al., 2002). There 
are four members of the Janus kinase family: JAK1, JAK2, JAK3 and Tyk2. Each has 
distinct functions based on its ability to bind different cytokine receptors.  
The gene for JAK3 has been mapped to human chromosome 19p12-13.1 and encompasses 
23 exons. Furthermore JAK3, is involved in the signal transduction pathways of the 
interleukin (IL) -4, IL-7, IL-9 & IL-15 receptors (Fig1. 2). 
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Fig. 1.2:  Schematic organization of the mouse JAK3/RLF gene locus, indicating  
            relative positions of the JAK3 (hatched boxes) and RLF (open boxes) 
              exons, positions of PCR primers used, and locations of potential  
 transcription factor binding sites. Also shown above is the original JAK3       
             genomic structure (accession number U71201) (Koskimies, et al., 1997). 
 The mouse RLF promoter and factors controlling the RLF gene expression were 
examined by using 2.1 kb of the 5’ flanking region of the mouse RLF gene 
(Zimmermann, et al, 1998). It was revealed that sequences designated SF-1/1, 
SF-1/2 and SF-1/3 regions are homologous to the consensus binding-site of the 
steroidogenic factor-1 (SF-1). 
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During the course of a study by Pasi Koskimies et al on the mouse RLF gene in 1997, it 
was discovered that a cDNA product had exon two of RLF fused to the 3’end of JAK3. 
More extensive Southern blot, polymerase chain reaction and sequencing analysis revealed 
that the published mouse sequence for exon 23 of the JAK3 gene in fact consisted of two 
exons, 23A and 23B , separated by an additional novel intron of 2.2 kb. Within this intron 
the mouse RLF gene is encoded (Koskimies, et al., 1997). The two overlapping transcripts 
appear to use different polyadenylation signals in the common 3’ untranslated region of 
exon 23B (Koskimies, et al., 1997). 
 
In addition, the mouse RLF gene resides wholly within the JAK3 genomic region. This 
intriguing result indicates that the genomic organization and transcription of the RLF gene 
is more complex than previously thought.  Therefore, a detailed analysis of the RLF gene 
region could provide insights into this complex genomic arrangement. In addition, the 
results of detailed structural examination could have important implications for the 
function and evolution of the peptide hormone gene.  This examination could also form the 
basis for investigating possible heterogeneity in the human RLF gene. 
 
1.3.1 RLF receptor  
The receptors for the relaxin family were uncharacterised until recently. However, the 
insulin receptor has been well characterised as a tyrosine kinase receptor. The dogma 
believed that the relaxin receptor would also be a tyrosine kinase receptor, similar to the 
insulin receptor. A study carried out by Hsu et al in 2002, finally demonstrated that relaxin 
activated two previously orphan leucine rich repeat containing heterotrimeric guanine 
nucleotide binding protein- coupled receptors (GPCR), LGR7 and LGR8 ( Hsu, et al., 
2002).  
 11 
In further studies, LGR7 was shown to be the relaxin receptor (Kumagai, et al., 2002; Ivell 
and Einspanier, 2002; Hsu, et al., 2003), whereas LGR8 is a relaxin like factor (RLF) 
receptor (Hsu, 2003) (Fig. 1.3). Therefore, RLF is a circulating hormone that binds to 
specific membrane-bound uterine receptor LGR8. In addition to the gubernaculums, a 
number of human tissues including testis, ovary, brain and kidney also express LGR8 
mRNA, suggesting additional roles for the RLF-LGR8 system in these tissues (Kawamura, 
et al. 2004; Fu, et al., 2005). Knockout mice (Great mice), whose LGR8 gene has been 
deleted, have an identical cryptochrid phenotype to that of the RLF knockout mice 
(Overbeek, et al., 2001; Gorlov, et al., 2002). 
 
 The RLF-LGR8 system appears to be evolutionarily modern (Scott, et al., 2005; 
Wilkinson, et al., 2005). There is no evidence for such a system in any sub-mammalian 
vertebrate or invertebrate and it would appear to have evolved parallel to the evolution of 
the relaxin LGR7 system in female physiology (Anand-Ivell, et al., 2006). 
It is believed that the principal receptor-binding site resides within its B-chain. It was 
subsequently observed by Del-Borgo et al that the linear B-chain alone bound to LGR8 and 
was able to antagonise RLF stimulated cAMP accumulation in HEK-293T cells transiently 
expressing LGR8 receptor (Del-Borgo, et al., 2006). Studies have indicated that RLF binds 
and activates LGR8 in the gubernaculums to elicit an increase in cAMP production and 
growth of this ligaments (Kumagai, et al., 2002; Kubota, et al., 2002). Over-expression of 
the RLF gene in female mice results in descent of ovaries into the inguinal region due to an 
overdeveloped gubernaculum, consistent with the actions illustrated above. Although 
female RLF null mice exhibit impaired fertility (Nef and Parada, 1999), female LGR8 null 
are fertile (Gorlov, et al., 2002), indicating that RLF is involved in female fertility but that 
there may be redundant signaling systems involved. It has recently been demonstrated that 
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RLF gene expression is increased in patients with advanced thyroid carcinoma (Hombach-
Klonisch, et al., 2003), although the significance of this is yet to be verified.  
 
In rats, the action of gonadotropin on the maturation of oocytes and the suppression of 
male germ cell apoptosis in the testis has recently been revealed to be mediated by RLF.  
In mammals, it is well established that oocyte maturation and male germ cell survival is 
controlled by luteinizing hormone (LH) (Richards, et al., 2002; McGee and Hsueh, 2000). 
However, because LH does not act directly on germ cells, paracrine factors are likely to 
mediate its action. It has been demonstrated that LH acts on ovarian theca and testicular 
leydig cells to produce RLF (Kawamura, et al. 2004). RLF then binds to the LGR8 
receptor on germ cells to activate the inhibitory G protein (Gi) leading to decreased cAMP 
production. This is in stark contrast to LGR8 in gubernacular cells, which is coupled to 
stimulatory Gs protein (Del-Borgo, et al., 2006). In female rats RLF treatment was 
revealed to initiate meiotic progression in arrested oocytes in vitro and in vivo (Del- Borgo, 
et al., 2006). On the other hand, RLF treatment was found to suppress male germ cell 
apoptosis induced by gonadotropin withdrawal in male rats treated with a Gonadotropin 
releasing hormone (GnRH) antagonist in vivo. These results demonstrate that RLF has a 
potential clinical application as a specific regulator of fertility and LGR8 antagonists have 
the potential to be highly specific contraceptives (Del-Borgo, et al., 2006). To date, there 
have been few structure function studies for RLF, with a paucity of information regarding 
the residues or regions required for specific receptor binding (Del- Borgo, et al., 2006). 
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Fig. 1.3:  Schematic diagram showing the structure of the RLF receptor (LGR8). 
The receptor comprises of 4 main components included: amino terminal 
ectodomain which contains the leucine -rich repeat and cysteine-rich 
regions, followed by the 7-transmembrane domain (TM1-TM7), and the 
cytosolic carboxyl terminus. (Ivell and Einspanier, 2002).   
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1.4 Aims and hypothesis 
A detailed analysis of the rat RLF gene region and nucleotide sequences could provide 
insights into this complex genomic arrangement. In addition, the results of detailed 
structural examination could have important implications for the function and evolution of 
the peptide gene.   
 
The RLF gene consists of two exons and one intron, which is endogenously expressed to a 
high level exclusively in Leydig cells.  The mouse genomic region for RLF is embedded 
within the 3’ end of the mouse JAK3 gene, which is expressed predominantly in the 
lymphoid tissues (Koskiemis, et al., 1997).  Therefore, it is of great interest to investigate 
the rat RLF promoter and the complete RLF gene with respect to localization near the 
JAK3 gene region.  This complex genomic arrangement would then be compared to the 
situation in the human genome. 
 
RLF is a circulating hormone that binds to a specific membrane-bound receptor LGR8.  
Studies have indicated that RLF binds and activates LGR8 in the gubernaculums to elicit 
an increase in cAMP production and growth of this ligament (Kumagai, et al., 2002; 
Kubota, et al., 2002).  Following up the possibility of an inhibitory effect of the receptor on 
the nuclear factor κB (NFκB) reporter pathway with RLF, this thesis has focused on further 
examining the effect of RLF on the NFκB signalling pathway when it is also stimulated 
with serum. 
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CHAPTER 2 
 
2.0 Materials and methods: 
 
2.1.1 DNA Preparation 
One gram of rat liver tissue was placed in a 1.5ml eppendorf tube containing 500 µl of 
proteinase K solution (0.5 mg/ml Proteinase K in 0.2 % w/v SDS / 0.2 M NaCl / 0.1 M 
Tris HCl PH 7.5 / 5 mM EDTA). The solution was incubated overnight at 55oC in a water 
bath. Five hundred microliters, of phenol (equilibrated with 1M Tris-HCl pH 8.0) was 
added and samples vigorously mixed by shaking for 15 seconds. Samples were centrifuged 
in a micro- centrifuge for 5 minutes at 14,000 g. force to separate the phases.  
Approximately 500 µl of the upper aqueous layer was removed and placed into a fresh 
eppendorf tube and 500 µl of isoamyl/chloroform (1part in 24) added and again vigorously 
mixed.  The samples were centrifuged as before and approximately 500 µl of the upper 
layer removed and placed into a fresh eppendorf tube, to which was added 50 µl of 3M 
sodium acetate (pH 7.4) and 500 µl of 100% cold (-20oC) ethanol. Samples were then 
gently mixed by inversion of tubes to induce DNA precipitation.  DNA was then removed 
with a sterile toothpick and washed in 500 µl 70% ethanol, then placed in a new eppendorf 
tube.  DNA was dried in a speedvac for 5 minutes then resuspended in 100 µl sterile milli-
Q water.  The DNA was resuspended by placing at 55oC in a water bath for 25 minutes and 
stored at 4oC.  DNA was diluted 1/10 in sterilised milli-Q water for PCR reactions.  
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2.2.2 Polymerase chain reaction (PCR) for the rat RLF gene 
Rat genomic DNA  was used as a template in PCR experiments to generate RLF DNA 
fragments, which encompass the whole gene.   
Two synthetic primers, RLF TATA (5’-TAAGGAGCGTCCTTACCCGCT-3’) 
and RLF STOP (5’-TCAGTGGGGACACAGACCCAA-3’) were designed on the 
published mouse, pig and human RLF cDNA sequences respectively to the two exons and 
they spanned the intron. (Fig.2.1 and 2.2) 
The primers were used in a PCR reaction to generate and amplify a rat genomic sequence 
obtained from rat liver. An aliquot of DNA (1µl of ~100ng DNA) was used in a 50µl PCR 
reaction containing 1.5mM Mg2+ ion concentration, a mixture of 5.0µl each of PCR buffers 
A and B (Life Technologies Inc., MD, USA), 4.0µl of 2.5mM dNTPs (Boehringer 
Mannheim, Germany), 1.0µl Elongase (Invitrogen USA), 1.0µl Oligonucleotide primers 
(0.1µg/µl) and 37.0µl of sterile deionised water. The reaction was pre-denatured at 94 oC 
for 5 min. in the M. J. Research PTC-200 (USA) thermal cycler.  The PCR reaction was 
carried out for 40 cycles with the following conditions:  94oC for 0.5 min denaturing, 65oC 
for 0.5 min annealing and 68 oC for 3 min extension period. This was followed by a final 
post-PCR extension period at 72 oC for 5 min.  
The Reaction buffer was made as a master mix from which 49 µl was added to each tube 
containing 1 µl. DNA.  A “no DNA” sample was included as a negative control.   
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Fig. 2.1: Alignment of the published cDNA sequences between pig accession number 
X68369, human accession number NM_005543 and mouse RLF accession 
number NM_013564. The figure shows the position of the primers designed 
according to the most conserved regions. Preference was given to mouse 
sequence in designing the primers, considering that rat is more closely related to 
mouse (rodents) than pig or human. The TATA box and the first translation 
initiator codon ATG are boxed also boxed the TGA stop codon in 3’ end. 
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      RLF TATA → ←   RLF 
STOP  
                                                                                                            
           ← RLF SEQ1  RLF SEQ2 → 
                         EXON I                                        EXON II 
                                   
GENE                                    INTRON 
                              ~ 175 bp                   ~ 800 bp ~ 250 bp 
 
 
                               B                    C                     A 
CODING 
PROTEIN 
 
 
RLF TATA: 5’- TAA GGA GCG TCC TTA CCC GCT -3’ 
RLF STOP: 5’- TCA GTG GGG ACA CAG ACC CAA -3’ 
RLF SEQ1: 5’- TCC ATG AGG ACT CTA GTC TT -3’ 
RLF SEQ2: 5’- AGG GAC TTA AGC TGA TTT CT -3’ 
 
 
Fig.2.2:  Schematic diagram showing the positions of the synthetic oligo nucleotides  
 used for PCR and nucleotide sequencing. The sequencing primer RLF TATA 
generates overlapping sequence with RLF STOP within the intron region. Extra 
sequencing primers RLF SEQ1 and RLF SEQ2 were designed to span the 
remaining overlap sequence in both directions to insure full sequence of the  
 whole gene. 
 
 
 
 19 
2.2.3 Agarose gel electrophoresis of DNA and purification 
Analytical agarose (0.8% w/v) was dissolved in Tris acetate, EDTA (TAE) buffer by 
heating, cooled and ethidium bromide added to a final concentration of 0.5 µg/µl.  The 
mixture was then poured into a gel caster with the appropriate comb and allowed to set.  
The comb was removed and the gel was placed in an electrophoresis tank submerged in 1 x 
TAE buffer. 3µl of loading buffer (Bromophenol blue and xylene cyanol dyes 0.25% w/v 
in 50% glycerol) was added to each DNA sample, mixed and added to gel wells. 
Electrophoresis was carried out for 60 minutes at 100 volts and DNA visualised under UV 
light (310 mm).  The correct size band was excised from the gel and DNA extracted by 
following the supplied protocol of the QIAGEN QIAquick gel extraction kit Qiagen FL, 
USA 
 
2.2.4 Determination of DNA concentration 
Two microliters of extracted DNA was added to 1ml of autoclaved water and thoroughly 
mixed (dilution 1 in 500). The absorbance was measured using a spectrophotometer 
reading at wave length of 260 nm for DNA. The OD at 260nm allows calculation of the 
concentration of nucleic acid in the sample. An OD of one corresponds to 50 
micrograms/mL for dsDNA.  The sample OD converted to a concentration using the 
formula:  (DNA) mg/ml = OD at 260nm X dilution factor (500) X 50 [dsDNA]  
 
2.2.5 Sequencing protocol    
The amplified and gel purified PCR product was sequenced using the ABI-PRISM BigDye 
terminator cycle sequencing ready reaction kit with AmpliTaq® DNA polymerase (PE. 
Applied Biosystems USA). The PCR sample was sequenced in both directions using 
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specific primers RLF TATA, RLF STOP, RLF SEQ1 and RLF SEQ2 which were  based 
on the sequence of each end of the fragments. The sequencing reaction was carried out in 
0.5ml PCR tubes.  An aliquot of 4.0µl of the DNA template (25ng/µl) was added to 20.0µl 
sequencing reaction mix containing 8.0µl of Terminator Ready Reaction Mix (PE. Applied 
Biosystems), 1.0µl of oligonucleotide primer (= 3.2 pmol) and 7.0µl of sterile deionised 
water. 
The primer concentration were determined by applying the following formula:  
 
                   100 x OD 260 denominator values = molar 
pmol/µl =                                                                       extinction coefficients at 260nm 
                    1.54 nA + 0.75 + 1.17nG + 0.92nT                  n=no. of each base in the 
primer 
 
Primers : 
 RLF TATA:  5’- TAA GGA GCG TCC TTA CCC GCT -3’ 
 RLF STOP:  5’- TCA GTG GGG ACA CAG ACC CAA -3’ 
 RLF Seq1:  5’- TCC ATG AGG ACT CTA GTC TT-3’ 
 RLF Seq2:   5’- AGG GAC TTA AGC TGA TTT CT-3’ 
 
This reaction mix was mixed well on a vortex and briefly spun in a micro centrifuge. The 
sequencing was done on the M J Research PTC-200 thermal cycler according to the 
following program:  One cycle of 96oC for two minutes, followed by 25 cycles, first at: 
96oC for 10 seconds denaturing, 50oC for five seconds annealing and final extension period 
at 60oC for 4 min.  Rapid cooling to 4oC completed the reaction. The samples were stored 
at -20oC, where necessary. 
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2.2.6 Ethanol Precipitation to remove excess BigDye terminators 
The purpose of purification is to completely remove unincorporated dye terminators prior 
to electrophoresis. Excess dye terminators in sequencing reactions obscure data in the early 
part of the sequence and can interfere with base-calling. In a sterile 1.5ml micro-centrifuge 
tube 2.4µl sodium acetate, (2.5M, pH5.2) and 50.0µl ethanol (100%) were added and 
mixed thoroughly by vortexing.  To this tube was added the entire content of each of the 
PCR reaction tubes. The reaction tube was washed with 10µl of sterile water and this was 
also transferred to the microcentrifuge tubes. The samples were vortexed and placed on 
bench for 10 min to precipitate at room temperature. The samples were then centrifuged at 
14000 g for 20 min at 4 oC.  The ethanol was carefully removed without disturbing the 
pellet. The pellet was then rinsed by adding 250µl ethanol (75%) to the side away from the 
pellet.  All the ethanol was removed by aspiration and the tubes centrifuged at 7000 g for 2 
min (at room temperature), to collect any remaining ethanol at the bottom. The remaining 
ethanol was removed. The samples were air-dried with the tubes upside down until the 
ethanol had evaporated. 
 
2.2.7 Sequence determination 
The sequencing reactions were run on an Applied Biosystems 377 machine (Howard 
Florey Institute, University of Melbourne). Multiple sequencing reactions were performed 
using both forward and reverse primers. Nucleotide sequence chromatograms were 
generated for each PCR sample analysed.  
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2.3.1 Maintenance of HEK 293 human embryonic kidney cell line 
Human embryonic kidney cell lines (HEK 293) were supplied by the American Type 
Culture Collection (ATCC). Cells were cultured and maintained in RPMI-1640 medium 
(Life Technologies Inc., USA) supplemented with 10% fetal bovine serum (FBS) and 15 
µg/ml Gentamycin  at 37°C in humidified incubator with 5% CO2. Cells at 80-90% 
confluence were split into 75cm2 flasks for continues culturing or into 24 well plates for 
experiments. For longer storage, cells were trypsinised and aliquots of approximately 5 X 
106 cells in RPMI media (RPMI media includes 10% FBS, 10% dimethyl sulfoxide 
(DMSO) and 1% Gentamycin) were cryopreserved in liquid nitrogen. 
 
2.3.2 Transformation of Escherichia coli with Expression Vectors 
Mercury Pathway Profiling System was obtained from CLONTECH Laboratories Inc. 
(USA). Each vector contains a different cis-acting enhancer element responsible for a 
particular signalling pathway (Figure 2.3). Control vector - pCMVβ (Figure 2.4) was also 
obtained from CLONTECH Laboratories Inc. (USA). Expression vector (pCDNA 3.1-Zeo) 
(Figure 2.5) containing the full sequence of LGR8 was a gift from Dr. Aaron Hsueh, 
Stanford University School of Medicine, Stanford, USA. These vectors were introduced 
into competent Escherichia coli (E.coli) cells strain DH5α via electroporation using the 
BioRad GENE Pulser® II electroporation system (Bio-Rad Laboratories Inc., USA). The 
E.coli cells were made competent as described by Smith et al (1990). The pulse voltage 
was set at 2.5 kv, capacitance at 25 µF, and 200 ohms (Ω) resistance. The time duration of 
the electroporation was 4.5 to 5 ms constant. One µl of  plasmid DNA (1 µg/µL) was 
mixed with 40µL freshly thawed electro-competent DH5α cells in a pre-chilled 0.2cm 
electroporation cuvette and then electroporated. Immediately after electroporation 960 µL 
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of Luria-Bertani (LB) media (10g Bacto-tryptone, 5g yeast extract, 10g NaCl PH 7.5 made 
to 1 litre with water) was added and incubated at 37° C for one hour. One hundred µL were 
then transferred to LB agar plates that contained 100 µg/mL ampicillin.  
2.3.3 Escherichia coli (E. coli) cultivation and plasmid DNA isolation 
LB media plates consisted of 500ml dH2O, 5 g. Tryptone, 2.5 g. yeast extract, 4 g. NaCl, 
0.2 ml. of 2 M NaOH, 1.5% agar & AMP (100µg/ml). DH5α E.coli strain containing 
plasmid DNA were streaked on the LB plates, and incubated at 37°C overnight.  The 
colonies were counted and an appropriate quantity of LB broth was added to resuspend the 
bacteria. The plasmid DNA was isolated using the Bio Rad Quantum prep plasmid kit, 
according to the manufacturer’s recommendations (Bio Rad, USA). Two milliliter of 
resuspended cells containing DNA were transferred to a micro centrifuge tube.  The cells 
were pelleted by centrifugation for 30 seconds.  The supernatant was discarded, and 200µl 
of the cell resuspension solution was added and vortexed.  250µl of the cell lysis solution 
was also added and mixed until the cell lysis occurred.  Another 250µl of the neutralisation 
solution was added and mixed until a visible precipitate was formed, and pelleted for 5 
minutes by centrifugation.  200µl of the matrix suspension solution was added and mixed 
by pipeting up and down. The suspension was immediately transferred into a spin filter 
placed into a micro centrifuge tube and centrifuged for 30 seconds.  The filtrate was 
discarded; the spin filter replaced back into the same tube, and 500µl of wash solution was 
added, and centrifuged for 2 minutes.  The filter was then replaced into a new micro 
centrifuge tube, and 100µl of deionized water was added.  The DNA was eluted by 
centrifugation for 30 seconds. 
 
 24 
 
 
Fig. 2.3: A diagram of the reporters and their responsible pathways. The reporters  
 are divided into three groups based on the type of signaling transduction 
 they are involved in. Each reporter construct contains a different DNA  
 enhancer, which is known as the transcriptional factor response element. 
 (Adapted from Chan 2002). 
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Figure 2.4:  The restriction enzyme map of the control vector, pCMVβ 
(CLONTECH Laboratories Inc., USA). The SV40 early promoter and 
enhancer initiate the transcription of the lacZ gene which encodes for 
the enzyme β-galactosidase (β-gal). The enzyme hydrolyses the 
substrate, ONPG, releasing the product 2-nitrophenol which is 
measurable by spectrophotometry. The ampilicillin resistance (Ampr) 
gene confers the transformed bacterial clones for positive selection. The 
restriction enzyme sites are also shown on this map. 
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Figure 2.5. The restriction enzyme map of the LGR8 expression vector, pcDNA3.1-
Zeo (Invitrogen Inc., USA). The full DNA sequence of human LGR8 
was inserted into the multiple cloning site as shown with (+) being the 
forward and (-) being the reverse orientation. The human 
cytomegalovirus (PCMV) immediate-early enhancer-promoter induces 
high-level constitutive expression of the down-stream insert. The 
bovine growth hormone polyadenylation signal (BGH pA) allows 
efficient transcription termination and enhanced mRNA stability. Also 
shown is the selectable marker for Zeocin. 
  
.                                  
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2.3.4 Transfection of HEK 293 cells 
One day prior to transfection, the cells were split into 24 well plates. On the day of 
transfection, the media was replaced with fresh RPMI 1640 without phenol red (with 1% 
FBS or without) for at least one hour before transfection. Transfection was then performed 
using LipofectamineTM 2000 (Invitrogen Corporation, USA). Two microliters (2 µl) of 
Lipofectamine was added to 0.6 µg of plasmid DNA mixture (0.2 µg pCMVβ control 
vector + 0.2 µg pathway profiling reporter vector + 0.2 µg LGR8 expression vector) for 
transfection of cells. All procedures were carried out according to the manufacturer 
protocol. The cells were maintained in RPMI 1640 with 1% fetal calf serum (FCS) or 
without FCS at 37oC for 24 hours. 
 
2.3.5 Ligand activation of LGR8 
Synthetic rat RLF peptide was kindly supplied by Dr Ross Bathgate of Howard Florey 
Institute of Experimental Physiology and Medicine, Victoria, Australia. A fresh RPMI-
1640 media supplemented with 1% Gentamycin, 1% FCS or without serum. Rat RLF was 
resuspended in sterilized H2O and added to the transfected cells at a final concentration of 
10-7 M. RLF should activate the receptors for reporter expression. Cells were incubated at 
37oC at 5% CO2 for 24 Hours. 
 
2.3.6 Reporter expression assay 
Media of the cultured cells, which contained the secreted alkaline phosphatase (SEAP), 
were harvested from the wells and transferred into micro-centrifuge tubes and centrifuged 
at 12,000 g for 2 minutes. The supernatant then stored at -20oC until assayed.  
The supernatant was assayed for reporter protein by the amount of SEAP product 
expressed from signaling pathway reporter genes using 4-Methylumblliferyl Phosphate (4-
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MUP) substrate system (Sigma – Aldrich Inc., Australia). 25µl of the collected medium 
was mixed with 25µl of 1 x dilution buffer from the Great Esc Ape SEAP Fluorescence 
Detection Kit (CLONTECH Laboratories Inc., USA). To remove the endogenous alkaline 
phosphate, the samples were incubated at 65oC for 30 minutes (SEAP is heat stable). When 
samples had cooled down 97µl assay buffer (2M Diethanolamine + 1mM MgCl2 + 20 mM 
Homoarginine) and 6µl of 4-MUP were added to the samples. Samples were then 
incubated in the dark at room temperature for 1 hour before reading. The fluorescent 
product methylumbelliferone was measured using fluorescence spectrophotometer with 
excitation of 360 nm and emission peaks of 449 nm.  
 
2.3.7 Cell lysate and transformation efficiency assay  
After the removal of the media from each well the cells were lysed by adding 200 µl of 
lysis buffer (0.01 M phenylmethylsulfonyl fluoride (PMSF), 0.2 unit’s aprotinin, 2 mM 
Magnesium Chloride (MgCl2), 1 mM EGTA, 1% Triton X100 and 50 mM Tris, PH 7.5). 
The plate was then placed on a shaker at moderate speed for 45 minutes. The lysate was 
then transferred into microcentrifuge tubes and centrifuged at 14,000 g for 2 minutes. 
Carefully, the supernatant was transferred into new tubes and stored at minus 20oC until 
used. The transfection efficiency was assayed by quantifying the amount of  β - 
galactosidase produced from the control vector pCMVβ described in Sambrook et al 
(1989) which uses the o-nitrophenyl-β-D-galactopy anoside (ONPG) as substrate). 
Absorbance of the product 2-nitrophenol, was then measured at 420nm using a 
spectrophotometer (Shimadzu UV-160 UV visible spectrophotometer Shimadzu 
Corporation Australia). 
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2.3.8 Statistical analysis and data handling  
The obtained fluorescence absorption (in relative fluorescence units (RFU)) were 
standardised with the β-galactosidase transformation efficiency of the respective sample in 
a ratiometric manner. To compare the stimulation of RLF receptor one-way ANOVA was 
used. All experiments were repeated at least twice in triplicate using cells from 
independent transfections, and assays were performed in duplicate. 
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CHAPTER 3 
3.0 Characterization of the rat RLF gene structure and organization  
3.1 Introduction 
RLF is a hormone produced by testicular Leydig cells throughout life (Tremblay and 
Robert, 2005). During male embryonic life, it regulates an essential step of testicular 
descent, whereas in adults it acts as male germ cell survival factor (Tremblay and Robert, 
2005). Despite the proposed importance of RLF for male sex differentiation and function, 
very little is known about the molecular mechanisms that regulate its expression (Tremblay 
and Robert, 2005). So far, the only transcription factor studied is the nuclear receptor SF-1 
which is known to regulate mouse RLF promoter in Leydig cells.    
 
Preliminary data and the published mouse cDNA sequence (Pusch, et al., 1996) indicates 
that the mouse RLF gene is relatively small with exons of 175 bp and 250 bp, and one 
intron of approximately 800 bp (total 1225bp). 
 
Genomic DNA extracted from the liver of Sprague Dawley rat has been used in a 
polymerase chain reaction (PCR) to amplify a region, which encompasses the entire gene 
for relaxin like factor (RLF). This has been accomplished using long range PCR (Elongase 
polymerase) which had a proof reading activity.  The complete nucleotide sequence of the 
RLF sequences was determined by using fluorescent dye-terminator sequencing and 
specific primers. An alignment of both nucleotide and protein sequences were compared to 
the human and mouse RLF sequences. The genomic organization of this gene and the 
closely associated JAK3 tyrosine kinase gene was also investigated. 
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3.2 Results 
 
3.2.1 PCR for the rat gene 
PCR reactions were performed to amplify a DNA region, which corresponded to the entire 
rat RLF gene. The enzyme Elongase  which has a proof-reading active site and hence a 
12 – fold lower error rate than Taq polymerase was employed to minimize or avoid the 
introduction of errors into the DNA sequence, (Elongase Enzyme Mix, Invitrogen, 
USA). Synthetic oligonucleotide primers RLF TATA: 5’- TAA GGA GCA TCC TTA 
CCC GCT -3’ and RLF STOP: 5’- TCA GTG GGG ACA CAG ACC CAA -3’ were 
designed by aligning the previously published genomic sequences of mouse Ley I-L gene 
(Zimmermann, et al., 1997), human (Burkhardt, et al., 1994) and pig (Burkhardt, et al., 
1994) and choosing the most conserved region (Fig.2.1).  The estimated size of the PCR 
product is around 1200 bp, which corresponds to the entire gene of RLF. However, PCR 
screening produced multiple bands. A series of optimizing steps were undertaken in an 
attempt to rectify this problem. These steps included running magnesium gradients (Fig 
3.1) and range of different annealing temperatures (Fig 3.2). Different sets of primers were 
also designed and used. The different primers were designed according to the mouse RLF 
genomic sequence to amplify variable length products (Fig.3.3). However, no 
improvement in specificity was seen. Finally, a DNA fragment that been generated at 62°C 
annealing temperature and corresponded to the estimated size of 1200 base pair, was cut 
out and gel purified (Fig 3.2). Further polymerase chain reactions were performed using 
the purified DNA fragment as a template and the primers RLF TATA and RLF STOP. 
PCR experiments were carried out using two different annealing temperatures; 62°C and 
65°C.   
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The PCR samples were characterized by gel electrophoresis (Fig 3.4). 
The gel showed a single band at the expected size of 1200 bp with 65°C annealing 
temperature and double bands with the 62°C. The DNA fragment, which amplified at     
65°C (Fig. 3.4) was sequenced as described in the next section. 
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Fig 3.1: Rat sample ran at 62°C annealing temperature with RLF TATA and RLF stop  
 Primers, but different Magnesium Chloride (Mg2+) concentrations. 
 1 = No Mg2+. 
 2 = 1.5 mM Mg2+. 
 3 = 2.5 mM Mg2+. 
 4 = 3.5 mM Mg2+. 
 
 
 
 
 
1kb plus 
DNA marker 
(Invitrogen) 
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Fig 3.2: Using the RLF TATA forward primer and RLF stop back ward primer with  
 different annealing temperatures and 1.5 mM MgCl2. 
 1= RLF TATA/ RLF stop with 58°C annealing temperature  
 2= RLF TATA/ RLF stop with 60°C annealing temperature  
 3= RLF TATA/ RLF stop with 62°C annealing temperature  
 4= RLF TATA/ RLF stop with 65°C annealing temperature  
 A band or smear observed with 62°C at the estimated size of 1200 bp. 
 
 
 
 
1kb plus 
DNA marker 
(Invitrogen) 
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Fig. 3.3: A set of different primers was used to amplify RLF gene or some part of it. 
 Conditions: 1.5 mM Mg2+ concentration at 60°C annealing temperature. 
 1 = Alt 5’ and Alt 3’ predicted size approximately 623bp. 
       Alt 5’ seq.: CAG TGT AGC CAT CCA AGG AGA ACA GT 
       Alt 3’ seq.: GGT CCG GGT CTA GCG CGG GAT C 
 2 = Alt 5’ and UT 3’ predicted size approximately 760bp. 
       3’UT RLF seq.: CCT GAG CCC TGT GCT CCT TCA GT 
3 = 5’ UT RLF and 3’ 27 RLF predicted size approximately 1087bp. 
       5’ UT RLF seq.: CAT CCC TGC CCA CTG CCT CCT  
       3’ 27 RLF seq. : CGC ACC GCC TGA GCC CTG TGC TCC TTC 
 4 = Alt 5’ and 3’ 27 RLF predicted size approximately 772bp. 
 5 = 5’ 27 RLF and Alt 3’ predicted size approximately 628bp 
       5’ 27 RLF seq.: GCA TCC CTG CCC ACT GCC TGC CAC 
 
 
 36 
 
 
Fig.3.4: Agarose gel electrophoresis of a PCR performed using the purified DNA    
              fragment as a template and the primers RLF TATA and RLF STOP ran in 0.8 %   
               agarose containing 0.5 µg/µl ethidium bromide at 80 volts for one hour.           
               Lane 1 is 1kb plus DNA marker, lane 2 is a no DNA negative control. Lane    
              3 is sample one, this sample was discarded as it showed two bands. Lane 4   
              is PCR at 65°C showing a single band (in red circle) ran to expected size of  
             1200bp and used for all subsequent experiments.  
 
 
 
 
1 2 3 4 
3 
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3.2.2 Complete sequence   
 
As described previously in the methods section, the purified PCR band generated by 
primers RLF TATA and RLF STOP, has been sequenced on both strands using BigDye 
sequencing with an ABI Prism Ready Reaction Sequencing kit. The sequence of the 5’ 
and 3’end were generated using primers designed upstream from the original primers, 
which amplified the PCR genomic fragment (RLF TATA and RLF STOP). The 
sequencing primers generates overlapping sequence within the intron region, but did not 
span the entire gene. Additional sequencing primers RLF SEQ1 and RLF SEQ2 were 
designed based on the published nucleotide sequence of the mouse (Zimmermann, et al., 
1997) to extend beyond the remaining overlap sequence in both directions (Fig. 3.5). 
Sequencing data were obtained using the Applied Biosystems 337 machine (Howard 
Florey Institute, University of Melbourne). The sequence analysis was performed in 
triplicate for each primer and the results were manually checked first to identify any 
ambiguous reading output. The electronic results were then checked and a consensus data 
sequence for each primer generated. A contig of overlapping sequences were also 
assembled using WebANGIS multi align program. The original print out is enclosed in the 
appendix. The nucleotide sequence (Fig.3.6) was then translated in to amino acids to allow 
us to compare the protein sequence of the rat RLF with other published sequences 
(Fig.3.7). 
 
 
 
 
 
 38 
 
 
 
 
 
      RLF TATA → ←   RLF 
STOP  
                                                                                                            
           ← RLF SEQ1  RLF SEQ2 → 
                         EXON I                                        EXON II 
                                   
GENE                                    INTRON 
                              ~ 175 bp                   ~ 800 bp ~ 250 bp 
 
 
                               B                    C                     A 
CODING 
PROTEIN 
 
 
RLF TATA: 5’- TAA GGA GCG TCC TTA CCC GCT -3’ 
RLF STOP: 5’- TCA GTG GGG ACA CAG ACC CAA -3’ 
RLF SEQ1: 5’- TCC ATG AGG ACT CTA GTC TT -3’ 
RLF SEQ2: 5’- AGG GAC TTA AGC TGA TTT CT -3’ 
 
 
 
Fig. 3.5:  Schematic diagram showing the positions of the synthetic oligo nucleotides  
 used for PCR and nucleotide sequencing. The sequencing primer RLF TATA 
generates overlapping sequence with RLF STOP within the intron region. Extra 
sequencing primers RLF SEQ1 and RLF SEQ2 were designed to span the 
remaining overlap sequence in both directions to insure full sequence of the  
 whole gene. 
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3.2.3 Amino acid sequence alignment with published sequences of rat and  
         different species 
The rat RLF amino acid sequence of the deduced open reading frame was compared to the 
published mouse, human and pig RLF amino acid sequences. The full-length rat RLF 
cDNA sequence was 99.5 % homologous to the newly published rat RLF cDNA; accession 
number NM_053680 (Spiess et al in 1999) and had 100 % homology in the encoded 
protein sequence (Fig 3.8). In addition, the sequence was closely homologous (83%) to the 
mouse RLF cDNA (accession number NM_013564) and had 94% homology in the 
encoded protein sequence (Fig 3.9). However 18 nucleotides which encode 6 amino acids 
were absent in the mouse C domain compared to the rat. Amino acid sequence of rat RLF 
had 64 % homology to pig RLF (accession number X68369, Fig 3.10) and 60 % to human 
RLF (accession number NM_005543, Fig 3.11). 
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    1  AATTAAGGAG CGTCCTTACC CGCTGCCTCC TGCCACCATG CACGCACTGC 
   51  TGCTACTGCT GCTCCTGGCT CTAGGGTCCG CGCTGCGCTC CCCACAGCCC 
  101  CCGGAGGCGC GCGCCAAGCT CTGTGGTCAC CACCTGGTGC GTGCGCTGGT 
  151  GCGGGTGTGC GGTGGCCCGC GTTGGTCACC CGAGGCCACG CAGCCTGTGG 
  201  ACACCCGCGA CCGTGAGTGG GGACAGGCGG GGCAGATGGA TACGCATGGA 
  251  TAATCAAGTA GGAAGACGCT GGCATAGTGA CGCCCCCTCC TAATAGGACT 
  301  CTAAGACTAG AGTCCTCATG GACTTTTAAG TTTTCCCTCT TTTTGGATGT 
  351  TTGAGACGGA GTCTCAGTAG CCCAGGCTGG ACTCAGACTA ACAGTGTAGC 
  401  CATCCAAGGA GAACAGTGAA CTGCTTGCCT CACTTAGACT TGTGTACTTA 
  451  GCTGACTGGC ACGAGCCACC ACTTGGTTTA TTGTTTACTA AACAATACAA 
  501  GACAGACTCA CCTAGGAAAC CTAAAGTGAC TTCAAAGTCA CAGGAATCCT 
  551  GCCTCCGCAC CTCCAGTTCT GGGGTCACTG GGATATGACC CTCTTTGGGG 
  601  ATTGTGGGTG AGGACTCTAC CTCCAGGCCC AGAGAACAGA AGAGGACAGA 
  651  GGTCCCTGTG TCCCTGTGCC CAGCCCGGTG ATGTGGGAAT GTATGGCCCC 
  701  CTCCTGAAGC AGAGGGTGCC ATCCAAGGGG CCACAGGGCA AACCC.AAGA 
  751  CTGCGTGCAA CTTCTAGGGA CCTCACCCTT CCATGGCCAC AAACTGGGGT 
  801  GCACAGGAGG CATACAGGCA CACAGAGTTG GAGGTGAGTG TGGGCACCAG 
  851  CTGGGAGTTA TGTAGTATTC AGCAGGCGCT CTTTATGTGC TCCTTTGTCT 
  901  CTGGGAATAT AATAAATGTG GCCAGTATTT GGGAGGGACT TAAGCTGATT 
  951  TCTCCTTGCC CACAGGGGAG CTGCTGCAGT GGCTGGAGCA ACGACATCTC 
 1001  CTGCACGCGC TCGTGGCCGA TGCGGATCCC GCGCTAGACC CGGACCCCGC 
 1051  GCTGGACCCG CAGCTTCCTC ACCAGGCTTC TCAGCGCCAG CGCCGCAGTG 
 1101  TGGCCACCAA CGCTGTGCAC CGCTGCTGTC TCACTGGCTG CACCCAGCAA 
 1151  GACCTTTTGG GTCTGTGTCC CCACTGAAT 
 
 
 
Fig. 3.6: Rat-RLF nucleotide sequence of 1174 bp, obtained from genomic DNA  
 amplified with 5’ RLF TATA primer and 3’ RLF STOP primer. The first 
 translation codon (start codon) ATG is at position 37.  A TATA box 
 included within the sequence of RLF TATA primer boxed. 
 The stop codon TGA sequence is included within the RLF STOP primer 
 boxed. Exon 1 and exon 2 highlighted. The intron sequence is in blue. 
 
 
 
 
 
“TATA” Box “ATG” Start “TGA” Stop 
Exon
Intron
Exon2  
RLF TATA  primer 
RLF STOP  primer 
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            Signal peptide                 B-peptide 
                 10        20        30        40        50        60 
                  .         .         .         .         .         . 
       1 MHALLLLLLLALGSALRSPQPPEARA-----KLCGHHLVRALVRVCGGPRWSPEATQPVD  
       1 MRAPLLLMLLALGSALRSPETPEARA-----KLCGHHLVRTLVRVCGGPRWSPEATGLVE  
       1 MDPHPLTWALVLLGPALALSRAPAPAQEAPERLCGHHFVRALVRLCGGPRWSPEDGRAVA  
       1 MDPRLPAWALVLLGPALVFALGPAPTPEMRERLCGHHFVRALVRVCGGPRWSTGARRPAA  
         *    .   * *           * .      ***** **.***.*******      .     
         M        L L           A        LCGHH VR LVR CGGPRWS          
                           
                          C-peptide 
                  .         .         .         .         .         . 
      56 TRDRELLQWLEQRHLLHALVADADPALDPDPALDPQLPHQASQRQRRSVATNAVHRCCLT  
      56 TRDRELLQWLEERHLLHALVADVDPALDPEL---PREA-SQRERRSA--ATNAVHRCCLT  
      61 GGDRELLQWLEGQHLFHGLMASGDPMLVLAPQPPPQ--ASGHHHHRRAAATNPARHCCLS  
      61 GGDRELLQWLERRHLLHGLVADSNLTLGPGLQPLPQ--TSHHHRHHRAAATNPADYCCLS  
           ********* .**.* *.*. .. *                      ***    ***   
           DRELLQWLE  HL H L A     L                      ATN    CCL  C  
      
          A-peptide  
     116 GCTQQDLLGLCPH Rat 
     110 GCTQQDLLGLCPH Mouse 
     119 GCTRQDLLTLCPH Pig  
     119 GCTQQDLLTLCPY Human 
         ***.**** ***.                                                
         GCT QDLL LCP  CONSENSUS 
 
 
Fig. 3.7: Comparison of rat, mouse, pig and human RLF amino acid sequences. 
 The cleavage sites of the amino acid are marked by vertical arrows, the 
 predicted signal peptides in blue, B-peptide in purple, C-peptide in green 
 and A-peptide in red. Amino acids that occur in all four species at the 
 respective positions were taken as a consensus sequence and indicated by  
 asterisks. Residues conserved in A and B chain of all members within the 
insulin like hormone super family is indicated in red letters in the 
consensus. The receptor binding site motif is underlined.     
 
 
 
 
 
Rat 
Mouse 
Pig 
Human 
 
CONSENSUS 
 
 
 
Rat 
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Pig 
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BESTFIT of: Rat.RLF.Protein  check: 2388  from: 1  to: 180 
  
Rat.RLF.Protein 
  
 to: RAtus.rlfcDNApublishedprotein  check: 7378  from: 1  to: 198 
  
RAtus.rlfcDNApublishedprotein 
 
 Symbol comparison table: /dbase/gcg/gcgcore/data/rundata/swgappep.cmp 
 CompCheck: 1254 
 
         Gap Weight:  3.000      Average Match:  0.540 
      Length Weight:  0.100   Average Mismatch: -0.396 
 
            Quality:  267.0             Length:    180 
              Ratio:  1.483               Gaps:      0 
 Percent Similarity: 100.000   Percent Identity: 100.000 
 
 Rat.RLF.Protein x RAtus.rlfcDNApublishedprotein August 15, 19104 12:30.. 
 
                  .         .         .         .         . 
       1 MHALLLLLLLALGSALRSPQPPEARAKLCGHHLVRALVRVCGGPRWSPEA 50 
         |||||||||||||||||||||||||||||||||||||||||||||||||| 
       1 MHALLLLLLLALGSALRSPQPPEARAKLCGHHLVRALVRVCGGPRWSPEA 50 
                  .         .         .         .         . 
      51 TQPVDTRDRELLQWLEQRHLLHALVADADPALDPDPALDPQLPHQASQRQ 100 
         |||||||||||||||||||||||||||||||||||||||||||||||||| 
      51 TQPVDTRDRELLQWLEQRHLLHALVADADPALDPDPALDPQLPHQASQRQ 100 
                  .         .         .         .         . 
     101 RRSVATNAVHRCCLTGCTQQDLLGLCPH*RIVGLRWCVSIIPHLQLCQ*N 150 
         |||||||||||||||||||||||||||||||||||||||||||||||||| 
     101 RRSVATNAVHRCCLTGCTQQDLLGLCPH*RIVGLRWCVSIIPHLQLCQ*N 150 
                  .         .         . 
     151 TPGLPWRIPSLFIDPRNQGPQVLSPGSPIM 180 
         |||||||||||||||||||||||||||||| 
     151 TPGLPWRIPSLFIDPRNQGPQVLSPGSPIM 180 
 
 
Fig.3.8: Comparison of amino acid sequence between rat RLF top and published rat 
RLF bottom. Similarity and identity percentages are in red text and boxed. 
 Percent similarity represents the similarity between the two aligned 
sequences without the gaps.  Percent identity on the other hand represents 
the identical sequence taking into account the gaps and matches between 
the aligned sequences. 
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BESTFIT of: Rat.RLF.Protein check: 2388 from: 1 to: 180 
  
Rat.RLF.Protein 
  
 to: Mouse_RLF_protein_ncbi  check: 7039  from: 1  to: 122 
  
Mouse_RLF_protein_ncbi 
 
 Symbol comparison table: /dbase/gcg/gcgcore/data/rundata/swgappep.cmp 
 CompCheck: 1254 
 
         Gap Weight:  3.000   Average Match:  0.540 
      Length Weight:  0.100   Average Mismatch: -0.396 
 
            Quality:  171.2             Length:    128 
              Ratio:  1.403               Gaps:      1 
 Percent Similarity: 96.721   Percent Identity: 93.443 
 
 Rat.RLF.Protein x Mouse_RLF_protein_ncbi August 27, 19104 20:32  .. 
 
                  .         .         .         .         . 
       1 MHALLLLLLLALGSALRSPQPPEARAKLCGHHLVRALVRVCGGPRWSPEA 50 
         |:| |||:|||||||||||||||||||||||||||.|||||||||||||| 
       1 mraplllmllalgsalrspqppearaklcghhlvrtlvrvcggprwspea 50 
                  .         .         .         .         . 
      51 TQPVDTRDRELLQWLEQRHLLHALVADADPALDPDPALDPQLPHQASQRQ 100 
         ||||:||||||||||||||||||||||.      |||||||||:|||||| 
      51 tqpvetrdrellqwleqrhllhalvadv......dpaldpqlprqasqrq 94 
                  .         .         
     101 RRSVATNAVHRCCLTGCTQQDLLGLCPH 128 
         |||.|||||||||||||||||||||||| 
      95 rrsaatnavhrccltgctqqdllglcph 122 
 
 
Fig. 3.9: Comparison of amino acid sequence between rat RLF top and mouse RLF             
 bottom. The signal peptide is in blue. B-peptide in red. The C-peptide in 
green and the A-peptide in black. The red circle indicates 18 nucleotides 
which encode six amino acids that are absent in the mouse C domain. 
Similarity and identity percentages are in red text and boxed. Under- lined 
is the RXXXR motif.  Percent similarity represents the similarity between 
the two aligned sequences without the gaps.  Percent identity on the other 
hand represents the identical sequence taking into account the gaps and 
matches between the aligned sequences. 
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BESTFIT of: Rat.RLF.Protein  check: 2388  from: 1  to: 180 
  
Rat.RLF.Protein 
  
 to: Pig_RLF_protein_ncbi  check: 9937  from: 1  to: 131 
  
Pig_RLF_protein_ncbi 
 
 Symbol comparison table: /dbase/gcg/gcgcore/data/rundata/swgappep.cmp 
 CompCheck: 1254 
 
         Gap Weight:  3.000      Average Match:  0.540 
      Length Weight:  0.100   Average Mismatch: -0.396 
 
            Quality:  118.3             Length:    133 
              Ratio:  0.931               Gaps:      5 
 Percent Similarity: 77.869   Percent Identity: 63.934 
 
 Rat.RLF.Protein x Pig_RLF_protein_ncbi August 27, 19104 20:37  .. 
 
                  .         .         .         .         . 
       2 HALLLLLLLALGSAL...RSPQPP.EARAKLCGHHLVRALVRVCGGPRWS 47 
         |:| : |:| ||.||   |.|.|: ||..||||||:||||||:||||||| 
       4 hpltwalvl.lgpalalsrapapaqeapeklcghhfvralvrlcggprws 52 
                  .         .         .         .         . 
      48 PEATQPVDTRDRELLQWLEQRHLLHALVADADPALDPDPALDPQLPHQAS 97 
         ||...:|.. |||||||||..||:|:|:|.:|| |    .|.|| |.||| 
      53 pedgravaggdrellqwlegqhlfhglmasgdpml....vlapqpppqas 98 
                  .         .         .    
      98 ..QRQRRSVATNAVHRCCLTGCTQQDLLGLCPH 128 
           :::||..|||:.::|||.|||.||||.|||| 
      99 ghhhhrraaatnparhcclsgctrqdlltlcph 131 
 
 
Fig. 3.10: Comparison of amino acid sequence between rat RLF top and pig RLF     
 bottom. Similarity and identity percentages are in red text and boxed. 
 Percent similarity represents the similarity between the two aligned  
                  sequences without the gaps.  Percent identity on the other hand  
 represents the identical sequence taking into account the gaps and 
matches between the aligned sequences. 
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BESTFIT of: Rat.RLF.Protein  check: 2388  from: 1  to: 180 
  
Rat.RLF.Protein 
  
 to: Human_RLF_ProteinNcbi  check: 4185  from: 1  to: 131 
  
Human_RLF_ProteinNcbi 
 
 Symbol comparison table: /dbase/gcg/gcgcore/data/rundata/swgappep.cmp 
 CompCheck: 1254 
 
         Gap Weight:  3.000      Average Match:  0.540 
      Length Weight:  0.100   Average Mismatch: -0.396 
 
            Quality:  121.7             Length:    129 
              Ratio:  0.958               Gaps:      2 
 Percent Similarity: 72.222   Percent Identity: 60.317 
 
 Rat.RLF.Protein x Human_RLF_ProteinNcbi August 27, 19104 20:28  .. 
 
                  .         .         .         .         . 
       1 MHALLLLLL.LALGSALRSPQPPEARAKLCGHHLVRALVRVCGGPRWSPE 49 
         :.|: |:||  ||. || .:..|| |.||||||:||||||||||||||.| 
       5 lpawalvllgpalvfalgpaptpemreklcghhfvralvrvcggprwste 54 
                  .         .         .         .         . 
      50 ATQPVDTRDRELLQWLEQRHLLHALVADADPALDPDPALDPQLPHQASQR 99 
         | .|... |||||||||.|||||:||||.: .|:|: .  || .|:  :| 
      55 arrpatggdrellqwlerrhllhglvadsnltlgpglqplpqtshh..hr 102 
                  .         .          
     100 QRRSVATNAVHRCCLTGCTQQDLLGLCPH 128 
         ::|..|||:.: |||.||||||||.|||. 
     103 hhraaatnparycclsgctqqdlltlcpy 131 
 
 
 
 
 
Fig. 3.11: Comparison of amino acid sequence between rat RLF top and human 
   RLF bottom. Similarity and identity percentages are boxed. Percent    
                 similarity represents the similarity between the two aligned sequences  
 without the gaps.  Percent identity on the other hand represents the 
identical sequence taking into account the gaps and matches between the 
aligned sequences. 
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3.3.0 Bioinformatics analysis of the rat RLF and Janus kinase gene 
 (JAK3) 
Bioinformatics is the term that is used to describe the broad range of computer applications 
in biological science, including genomic sequencing, mapping, genome annotation and 
comparisons of multiple genomes (Goodman, 2002).     
 
3.3.1 Introduction and results 
JAK3 encodes Janus kinase 3, a tyrosine kinase that belongs to the Janus family of 
proteins, which is comprised of JAK1, JAK2, JAK3, and Tyk2.  These proteins bind to 
cytokine receptors and play an essential role in cytokine signaling (Chen, et al., 1997). 
JAK3 functions in signal transduction and interacts with members of the STAT (signal 
transduction and activators of transcription) family. It is unique in that it is expressed 
exclusively in hematopoietic cells (Gurniak and Berg, 1996).  
 
JAK3 associates with the common γ chain for receptors to interleukins 2, 4, 7, 9 and 15 
(Chen, et al., 1997).  Mutations that abrogate Janus kinase 3 function cause an autosomal 
SCID (severe combined immunodeficiency disease) (Bunting, et al., 1999).  
Genomic sequences have been cloned for the human, pig (Burkhardt, Adham et al. 1994), 
mouse (Koskimies, Spiess et al. 1997; Zimmermann, Schottler et al. 1997).  The RLF gene 
comprises two exons, with an intron interrupting the C-peptide coding domain, just as for 
insulin and relaxin genes. Surprising was the discovery that the RLF gene is colinear 
within the 3′ end of the gene encoding Janus kinase 3 (JAK3) (Koskimies, et al. 1997). 
Accordingly, the presumptive promoter region of the RLF gene is restricted within intron 
23 of the JAK3 gene. Certainly, a short region of only about 500–700 base pairs from 
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within this intron appears to be sufficient to govern specific RLF/INSL3 gene expression 
when transfected into mouse tumor Leydig cells (Koskimies, Spiess et al. 1997; 
Zimmermann, Schottler et al. 1997). 
The published mouse sequence for exon 23 of the JAK3 gene in fact comprises two exons 
23A and 23B, separated by an additional novel intron of 2.2 kb, and within this intron, the 
promoter region and exon 1 of the mouse RLF gene are encoded.  Also exon 2 is found to 
be syngeneic to exon 23B of mouse JAK3 gene (Fig.3.12) (Koskimies, et al, 1997).    
  
The mouse RLF promoter and factors controlling the RLF gene expression were examined 
by using 2.1 kb of the 5’ flanking region of the mouse RLF gene (Zimmermann, et al., 
1998). It was revealed that sequences designated steroidogenic factor 1 (SF-1/1), SF-1/2 
and SF-1/3 regions are homologous to the consensus binding-site of the steroidogenic 
factor-1 (SF-1).  Competition and antibody studies showed that the three SF-1 binding sites 
in the RLF promoter have similar binding affinities for SF-1 and it was identified that all 
three SF-1 binding sites are required for SF-1 mediated stimulation of RLF transcription 
thus demonstrating an essential role of SF-1 in transcriptional activation of the RLF 
promoter. 
 
Mouse Leydig (BLT-1), murine Leydig tumor cell line (mLTC-1), sertoli (MSC-1), 
granulosa (KK-1) and monkey Kidney (COS-7) cell lines, were transiently transfected with 
different RLF promoter reporter constructs indicated that as little as 0.7 kb of the region 
upstream of exon 2 of the RLF gene (and within the novel intron 23 of the JAK3 gene) is 
sufficient to account for cell-specific expression of the RLF gene (Koskiemis, et al., 1997). 
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Fig. 3.12: Schematic organization of the mouse JAK3/RLF gene locus, indicating  
            relative positions of the JAK3 (hatched boxes) and RLF (open boxes) 
              exons, positions of PCR primers used, and locations of potential  
 transcription factor binding sites. Also shown above is the original JAK3       
             genomic structure (accession number U71201) (Koskimies, et al., 1997). 
  The mouse RLF promoter and factors controlling the RLF gene expression 
   were examined by using 2.1 kb of the 5’ flanking region of the mouse RLF  
   gene (Zimmermann, et al, 1998). It was revealed that sequences designated  
  SF- 1/1, SF-1/2 and SF-1/3 regions are homologous to the consensus binding- 
  site of the steroidogenic factor-1 (SF-1). 
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This promoter region is specifically hypomethylated in Leydig cells compared to non-
expressing tissues (Koskiemis, et al., 1997). A high level of expression of the relaxin-like 
factor has been confirmed in the Leydig cells of the adult testes and at much lower level of 
expression in the luteal cells of the ovary through the cycle, pregnancy and in lactation 
(Balvers, et al., 1998). Furthermore, analysis of protein and mRNA expression through 
postnatal testicular development has indicated that moderate RLF expression is found in 
the fetal population of the Leydig cells. Therefore, fetal Leydig cells express RLF in an 
LH/human CG-independent fashion, whereas LH/human CG is essential to induce RLF 
expression in the adult Leydig cells. Similarly, the rat RLF gene is also closely linked to 
the JAK3 gene locus (Spiess, et al., 1999). As in the mouse (Pusch, et al., 1996; 
Koskimies, et a., 1997), the predicted 5’ UTR based on the location of the TATA-box in 
the upstream genomic sequence, would appear to be very short.  
 
Using bioinformatics and map viewer in the National Centre for Biotechnology 
Information (NCBI) database, the alignment and comparisons of rat, mouse and human 
genomic region from the last exon of the rat JAK3 gene (exon 23) to the first exon of rat 
RLF was analysed. Based on homology to the mouse sequence, this region includes the 
presumed upstream promoter of the RLF gene (Koskimies, et  al., 1997 ; Zimmermann, et  
al., 1997, 1998). For rat, the region chosen is between 18888160 bp to 18891460 bp, for 
the mouse the region is between 72072000 bp to 72075650 bp and for the human the 
region was between 17788300 bp to 17802010bp.  As it has been mentioned earlier, those 
regions were chosen because they correspond to the entire RLF gene and exon 23 of JAK3.    
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Substantial homology of 84% was observed between rat and mouse JAK3/RLF sequences 
over 1262 bp of mouse sequence (Fig.3.13) (Tokhi, 1999).  However, unlike the mouse 
where there is an overlap of the JAK3 and RLF (Fig.3.14), the rat RLF promoter is 
separated from the JAK3 gene by about 1kb (Fig.3.15). Also in humans, the RLF gene is 
4kb apart from JAK3 (Fig.3.16). 
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1 CGGAAGCCCC GGATGGCAAG CAGCCGGGAT GAGCGTGAGC TTGGTTCCTA 
51 TGATCTGGCT GTGTGACTTC AGGCGGGAAG CTGTCCCTCT CTGGGCCCCA 
101 GCACCCCCAA TCCCCTCTGG CCACCTCTTC CCATCATTCT TCCCTCCCAG 
151 AATGGGGATG TTAAATAAGT GACCCCAGGC TCTGCACGGT TGTCATTACC  
201 TCTGGAAATG CTTTACTAGC AAGTCTGCCT TCTGCAGAAC TCACAACCCC  
251 AGGTCCCAAG AGCACCCTAG ACTTGGCCAG AAACCCACCC AGACCCCCAG  
301 ACCCTCTCTT GACCCTAGGT CTGTGCCCAG TCCCTTGCTC TCCTGTCCAT  
351 GGGTTTCTTG GGGGCTGTGA AACCTCAGCA TGGGCTCCTG AAAGATTGGG  
401 TTCTGGGAGT GTTTGTTGAA TGAATAAATG AATTCAATAG AAAAATAGTT  
451 TGGGGTTGGA GTTGGGGTAT AGGAAAACTG GCTTACAATG GGGCAAGTGT  
501 GGGGATGGGG GAGCACAGCT GGGATTTGAG AGGTCTTGGC CAGACCCCAA  
551 GGACACCCCC TTTCCTTCCT TGCCCAGCTG CATGCAAGTC CTTGGCTCGC  
601 CAAGGGGAGC TGGTTTCCGG GCAAAGGCCA GTGCAAGGGG CAGAGGCCAA  
651 GGCTGGAGTT AGGTTGAACC AGCCCTGTGC ACCCCAGGAC AGTGCCTGCA  
701 GTCACCCACC ACAGTCAGGA GGTAGAGGAA CAGGAGAAGA ACCATTTAGA  
751 CTTATCCTCC CGTCTTCCAG CCTCAGTTTC CCTCTTTGAC AAAACCAAGT  
801 CATAAATACC TCCTCCCATC TCCTTCACAG CCCAAACTGC CTCCAACTTA  
851 CAGCAATTCT CCTGCCTCAG CTTTTTCACT GCTAGCAAGA CTGTCAACCT  
901 TACAAAAGGG GAAGGGACTT GGCTTGTTTT AAATGTTGGG GGGCGGCTCC  
951 TGGCACAGTG CTGCACCTGG GAGAGGGACT TCAGGGTCCC AAGCTGGACA  
1001 CACAGCCCCT GACCGTGACC TGAGCCTCGA CCTCCTCGGT GCTGCTCGTC  
1051 GTGTTCCCTC CAAGGCCCAT GGGCGGCGCA AGGCGGCTAT AAGGAGCGTC  
1101 CTTACCCGCT GCCTCCTGCC *ACCATGCACG CACTGCTGCTACTGCTGCTC  
1151 CTGGCTCTAG GGTCCGCGCT GCGCTCCCCA CAGCCCCCGA AGGCGCGCGC  
1201 CAAGCTCTGT GGTCACCACC TGGTGCGTGC GCTGGTGGGG GTGTTCGGTG  
1251 AACAACGGGG GCAATTCCAA AGGGATTTCT GTTTCCAAAA GGCCCTCAAT  
 
Fig. 3.13: Rat JAK3-RLF nucleotide sequence of 1300 bp, obtained from genomic DNA 
amplified with 5’ JAK.E23.1 primer and 3’ RLF-E1-IN primer. A transcription 
start site is located at 1120 denoted by *. The first translation codon ATG is at 
position 1124.  A TATA box and a SP1 binding site (GGGCGG) are found at 
positions 1088-1091 and 1071-1076, respectively.  The three putative binding 
sites for the transcription factor steroidogenic factor –1 (SF-1) are shown in 
bold, underlined letters at positions 654-659, 984-988 and 1063-1067.  The SRY 
transcription factor-binding site (AAAGGGG) is located at position 906 – 911 
(Tokhi, 1999).   
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Fig. 3.14: NCPI map viewer accession for showing the position of mouse  
                 RLF-JAK3 in chromosome 8.  
 
 
 
Fig. 3.15:NCPI map viewer accession for showing the position Rat RLF-JAK3 
                 in chromosome 16.  
 
 
Fig. 3.16: NCPI map viewer accession for showing the position of Human       
                  RLF- JAK3 in chromosome 19.  
RLF    
JAK3    
JAK3    
RLF    
RLF    
JAK3    
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3.5.0 CONCLUSION  
3.5.1 RAT RLF gene 
DNA fragments, which encompass the entire RLF gene, have been generated from 
genomic samples using the polymerase chain reaction (PCR). PCR experiments were 
performed on genomic DNA samples extracted from the liver of Sprague Dawley rat. 
  
The primers were designed to the two exons and they spanned the intron. These primers 
were designed according to the homology of rat RLF to the published mouse Ley I-L gene 
(Zimmermann, et al., 1997), human (Burkhardt, et al., 1994) and pig (Burkhardt, et al., 
1994). Substantial time was spent trying to optimise conditions and strategies. A purified 
PCR that showed a band which corresponds to the expected size of 1.2 kilo base has been 
sequenced (Fig.3.6) and translated to amino acids.  At the commencement of these studies 
(1998), there were no sequences published for rat RLF.  However, Spiess et al in 1999 
published the first rat RLF sequence.  The sequence that has been published was compared 
to the sequence in these studies and showed almost 100% similarities (99.5 % cDNA and 
100 % protein).  In addition, the sequence shows that the rat RLF gene and protein is 
closely homologous (83% DNA and 93% protein) to that of the mouse RLF (Fig.3.9). 
However, there is a significant difference between mouse and rat, as there is an insertion of 
18 nucleotides (6 amino acids) in the rat C domain (Fig.3.9), that is absent in the mouse C 
domain. However, this does not affect the reading frame (Spiess, et al., 1999). This 
insertion may have arisen by duplication (Spiess, et al., 1999).  
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The rat RLF amino acid sequence showed less homology to pig and human (64% and 60% 
respectively). In mouse the homology is 88 % in the signal peptide and 99% in the B 
peptide that includes the RALVR motif (Fig.3.9), which is considered to be involved in 
receptor interaction. Also the A peptide is extremely homologous (100%), while the C 
peptide is 55% homologous.  
 
In general, the putative receptor binding sequence RXXXR is highly conserved. That could 
explain the cross reactivity of RLF antibodies between different species. This study 
highlights that the rat RLF is very similar in its structural organization to that of the mouse, 
the pig and humans. 
 
3.5.2 RAT JAK3-RLF promoter region 
Janus kinase 3 (JAK3) is a member of the JAK family of intracellular tyrosine kinase that 
is physically and functionally coupled with several cytokine receptors (Notarangelo and 
Candotti, 2000; Notarangelo, 2005). Mutation in JAK3 leads to a form of severe combined 
immune deficiency (SCID), which is characterised by a lack of circulating thymus cells ( T 
cells) and Natural Killer cells (NK) with normal bone marrow cells (B cells) (Notarangelo 
and Candotti, 2000; Notarangelo, 2005). Thus, JAK3 plays a critical role in lymphoid 
development (Safford, et al., 1997). 
Comparison of the 3’ end of the human JAK3 gene with sequences reported in the Gene- 
bank database revealed that this sequence is 100% homologous with exon two of the 
human RLF gene (Safford, et al., 1997). Furthermore, RLF had been mapped to 
chromosome 19 in human, which is where JAK3 had also been mapped (Safford, et al., 
1997).   
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The published sequence for exon 23 of the JAK3 gene, in fact, comprises two exons, 23A 
and 23B, separated by an additional intron. Within this intron is the promoter and 
 exon 1 of the mouse RLF gene (Zimmermann, et al, 1998).  Although the RLF gene has 
been isolated and characterized from a wide variety of species, it appears that only the 
mouse RLF promoter region is fully sequenced (Koskimies, et al., 1997). Therefore, it was 
of great interest to investigate the rat RLF promoter region and compare it with that of the 
mouse and human.  
 
A sequence of 1300 base pair encompassing the 3’ end of exon 23 of rat JAK3 gene and 
exon 1 of the RLF gene, referred to as JAK3-RLF region, has been characterised (Tokhi,  
1999) and showed that the rat JAK3-RLF is relatively similar in its structural organization 
to the mouse JAK3-RLF gene (Koskimies, et al., 1997).  
 
The rat RLF gene is also found to be closely linked to the JAK3 gene locus (Spiess, et al., 
1999). By employing bioinformatics and NCBI database, an alignment and comparisons of 
rat, mouse and human genomic region comparing the last exon of the rat JAK3 gene (exon 
23) to the first exon of the rat RLF gene were performed. Based on homology to the mouse 
sequence, this region was found to include the presumed upstream promoter of the RLF 
gene (Koskimies, et al., 1997; Zimmermann, et al., 1997 and 1998). Furthermore, rat RLF 
also was found on chromosome 16, the same region in which JAK3 is found. Similarly, 
mouse RLF is found on chromosome 8, the same region that JAK3 is also localized. 
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CHAPTER 4 
Signaling pathways for Relaxin like factor (RLF)  
4.1 Introduction 
4.1.1 RLF receptor 
The receptor for RLF was unknown until recently. It was recently identified as the novel 
G- protein coupled receptor (GPCR) designated LGR8, also known as RXFP2 (Hsu, et al., 
2002). This receptor is structurally related to the GPCR LGR7 receptor, which is currently 
demonstrated to be the fundamental receptor for the relaxin hormone in almost all 
reproductive tissues (Anand-Ivell, et al., 2006).  
These receptors are unique in having a large N-terminal extracellular domain for ligand 
interaction (Hsu, et al., 1998; Hsu et al., 2000), which contain leucine-rich repeats. The 
human genome was screened to identify novel paralogues to LGR7 and, another LGR was 
discovered, named LGR8 (Hsu, et al., 2002), sharing approximately 60% sequence identity 
with LGR7. RLF appears to act similarly to the relaxin LGR7 system via its receptor to 
stimulate an intracellular increase in cAMP, both in vitro using cells over expressing 
cloned LGR8 (Kumagai, et al., 2002) and gubernacular and prostate cells with naturally 
expressed receptors (Klonisch, et al., 2005). When cells transfected with LGR7 and LGR8 
were stimulated with RLF, cAMP response was observed in cells with LGR8, but not in 
those with LGR7 (Kumagai, et al., 2002). This observation leads to the hypothesis that 
RLF was in fact the missing ligand for LGR8. 
 
Knockout mice (Great mice), with mutated or deleted LGR8 gene have a very similar 
cryptochrid phenotype to that of the RLF knockout mice (Overbeek, et al., 2001; Gorlov, et 
al., 2002). In addition, further breeding experiments have convincingly shown that no other 
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ligand is able to stimulate LGR8, as well as no other receptor is able to respond to RLF 
(Bogatcheva, et al., 2003). 
 
Structurally, the rat LGR8 has a high degree of sequence identity with its human and 
mouse receptor counterparts (Hsu, et al., 2002; Scott, et al., 2004).  RLF naturally induces 
growth and differentiation of the gubernacula during the intial trans-abdominal movement 
of the testes (Hutson, et al., 1997; Adham, et al., 2000).  In addition to the gubernaculums, 
a number of other human and rat tissues including testis, ovary, brain and kidney also 
express LGR8 mRNA, suggesting additional roles for the RLF-LGR8 system in these 
tissues (Fu, et al., 2005; Bogatcheva and Agoulnik 2005). However, little has been 
published on the regional and cellular distribution of LGR8 expression or the functional 
role of RLF in human or other species (Kawamura, et al., 2004). 
 
 Male mice homozygous for disruption of the RLF gene exhibited bilateral cryptorchidism 
(Nef and Parada, 1999; Zimmermann, et al., 1999), while female homozygote display 
impaired fertility with abnormal oestrous cycles (Nef and Parada, 1999). In contrast, 
transgenic over-expression of RLF caused ovaries to descend into the inguinal region due 
to of an overdeveloped gubernaculums (Adham, et al., 2002). 
 
A study by Ping Fu et al, has confirmed the presence of LGR8 mRNA in mesangial cells of 
mature renal glomeruli during development and in adulthood (Fu, et al., 2005). The profile 
of LGR8 expression in embryonic and adult rat kidney suggests a potential role for RLF in 
the regulation of renal development and the maturation or normal function of mesangial 
cells in rat and perhaps human kidney (Hsu, 2003).   
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In addition, the observation that RLF inhibits mesangical cell proliferation indicates the 
potential involvement of RLF/ LGR8 signaling in glomerular diseases, specially those 
involving excessive mesangial cell proliferation (Fu, et al., 2005). 
 
The research in this chapter is designed to provide an understanding of events leading to 
generation and transmission of a signal from the cell surface to the DNA first response 
elements within the cell. By using reporter gene technology we were able to measure the 
response of various signaling pathways to RLF. When RLF binds to its LGR8 receptor, a 
G protein-signaling pathway is activated leading to stimulation of adenylate cyclase (AC) 
which cause the cAMP to increase (Fig 4.1). 
 
Secreted alkaline phosphatase (SEAP) reporter genes allow pathway activation to be 
monitored by measuring the amount of SEAP present in the surrounding cell culture 
media. Each reporter gene has a specific enhancer element fused to a TATA like promoter 
region. Upon receptor activation, the induced intracellular signaling events lead to binding 
of the transcription factor to the response element, which leads in reporter expression (Fig 
4.2). 
 
In a study carried out by Stanley Chan in 2002, a variety of different reporter groups CRE, 
AP1, E-box NFAT, NFκB, SRE, ERE, GRE, RARE and TRE (Fig 4.3) were tested.  In this 
study it was observed that there was a decrease of the Nuclear factor of kappa beta (NFκB) 
reporter when cells were stimulated by RLF.  The results suggest that RLF may have an 
antagonist effect on the NFκB pathway (Fig 4.4).  Following up the possibility of 
inhibitory effect of the receptor on the nuclear factor κB (NFκB) reporter pathway with  
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RLF,  I have focused on further examining the NFκB pathway.  The aims of this study are 
to further investigate the effect of RLF with the NFκB signalling pathway and to test the 
stimulation effect of 1% FCS when treating cells with RLF. 
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Fig.4.1:  The different signal transduction pathways involved in the up-regulation      
of cAMP by the peptide hormone RLF. When RLF binds to its G protein-
coupled receptor, LGR8, a G protein signaling pathway is activated 
leading to stimulation of adenylate cyclase (AC) and an increase in cAMP. 
Binding of RLF to its receptor also may activate a tyrosine kinase pathway 
that inhibits the activity of a phosphodiesterase (PDE) that degrades 
cAMP (Ivell and Einspanier, 2002). 
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Fig. 4.2: Upon receptor activation, the induced intracellular signaling events lead   
               to binding of the transcription factor to the response element,  
               which leads in reporter expression. 
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Fig. 4.3: A diagram of the reporters and their responsible pathways. The reporters  
 are divided    into three groups based on the type of signaling transduction  
 they are involved in. Each reporter construct contains a different DNA  
 enhancer, which is known as the transcriptional factor response element.  
 (Adapted from Chan 2002). 
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Fig.4.4: Effect of RLF on signaling pathway reporter genes. The amount  
              of reporter protein in medium was quantified by the SEAP assay 
              and expressed degree of activation (RFU). RLF induced significant      
              reporter activation in cells transfected with CRE reporter. No significant   
              induction recorded with AP1, in contrast the NFκB reporter displays an    
              inhibitory trend, however it was not statistically significant in this study     
              (Chan, 2002). 
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4.2 Results 
 
4.2.1 The effect of RLF with the NFκB signalling pathway 
The experiments in this chapter illustrates the events leading to generation and 
transmission of a signal from the cell surface to the DNA response element within the cell.  
In utilizing the reporter gene technology, we were able to measure the effect of RLF on 
cAMP response element (CRE) and Nuclear factor κB (NFκB) signaling pathway 
reporters.  
 
4.2.2 Transient Transfection of Expression Vector into HEK293 cell line 
The efficiency of the transfection was determined by the β-galactosidase assay explained in 
section (2.3.7) in the materials and methods. As the transfection efficiency values vary in 
each experiment, the values obtained are used to standardise the fluorescence reading for 
the same experiment. 
 
4.2.3 Effect of RLF on signalling Pathway Reporter genes 
As described in the methods section (2.3.6), the Secreted Alkaline Phosphatase (SEAP) 
fluorescence assay was used to determine the effect of RLF on cAMP response element 
(CRE) and Nuclear factor κB (NFκB) signaling pathway reporters. As expected, the CRE 
reporter which is responsive to the protein kinase A (PKA) pathway showed a significant 
induction with RLF. No significant change was observed using the NFκB reporter, in the 
presence or absence of 1% serum (Fig.4.5). In addition, RLF did not statistically inhibit the 
NFκB reporter in the presence of 1% serum.  
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Fig.4.5: Effect of RLF on signaling pathway reporter genes. The amount of reporter  
 protein in medium was quantified by the SEAP assay and  expressed degree of 
activation. The fluorescence absorption (relative fluorescence units (RFU)) were 
standardised with the β-galactosidase transformation efficiency of the respective 
sample in a ratiometric manner. RLF receptor stimulation or inhibition was 
compared using ANOVA, Tukey-Kramer for multiple comparisons test and the P 
value is < 0.001, considered extremely significant. The experiments were carried 
out in triplicate for each reporter gene and performed twice (n = 6). 
* P < 0.001 
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4.3 Conclusions and future directions 
 
4.3.1 The effect of RLF with the NFκB signalling pathway 
Relaxin-like factor gene (RLF) is a circulating hormone that binds to specific membrane 
bound uterine receptors (Bullesbach and Schwabe, 1999a). It has been discovered that two 
orphan leucine-rich repeat containing G protein coupled receptors, LGR7 and LGR8, are 
cognate receptors for relaxin whereas RLF is a specific ligand for LGR8 (Hsu, et al., 
2002).  
 
The specificity of binding was confirmed by chemical cross-linking experiments 
(Bullesbach and Schwabe, 1999b). LGR8 stimulate cAMP production upon binding to its 
ligand (Muda, et al., 2005). When RLF binds to its LGR receptor, a G protein-signaling 
pathway is activated leading to stimulation of adenylate cyclase (AC) which cause the 
cAMP to increase (Fig. 4.2). 
 
The Secreted alkaline phosphatase (SEAP) reporter genes allow pathway activation to be 
monitored by measuring the amount of SEAP present in the surrounding cell culture 
media.  Previous studies in our laboratory had observed a slight inhibition of the response 
of the nuclear factor of κB (NFκB) reporter when cells were stimulated by RLF.  These 
results were interesting and unexpected.  Therefore further examination of the NFκβ 
pathway and its involvement in RLF signal transduction was required (Dschietzig, et al., 
2003).  
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Relaxin has been found to link tyrosine phosphorylation to phosphodiesterase and adenylyl 
cyclase activity (Bartsch, et al., 2001), all these effects are mediated via the relaxin 
receptor LGR7 and LGR 8, the receptor for RLF (Hsu, et al. 2002).  In addition, as LGR8 
is a member of the G protein-coupled receptor superfamily, the RLF receptor is expected 
to have a similar signaling mechanism to other members within the family. 
 
Nuclear Factor kappa Beta (NFκB) is a member of the rel family of transcription factors. 
NFκB plays a key role in the regulation of inflammatory response, apoptosis or 
tumorigenesis. NFκB is activated by a wide variety of different stimuli such as pro 
inflammatory cytokines, oxidant free radicals, inhaled particles, ultraviolet radiation and 
bacterial or viral products. In the inactive state, NFκB forms a cytoplasmic complex with 
Inhibitory kappa B Protein (IκB).  Upon stimulation, several types of kinases belonging to 
the mitogen-activated protein kinase (MAPK) family activate NFκB as follows: first, IκB 
is phosphorylated, dissociated and degraded.  The NFκB protein then translocates to the 
nucleus where it binds to its specific DNA motifs and initiates transcription of genes. 
NFκB regulates the expression of many genes which play a role in immunity and 
inflammation e.g. IL2, TNF, adhesion molecules and acute phase proteins. 
 
The pathways were examined by transiently infecting HEK 293 cells with cAMP response 
element (CRE) vector, along with LGR8 expression vector and the control vector pCMVβ. 
In conjunction, HEK 293 cells were transiently infected with the nuclear factor κB reporter 
(NFκB), LGR8 and pCMVβ.  The experiments was carried out in triplicate for each 
reporter gene and performed twice (n = 6). 
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Data were compared using ANOVA, Tukey-Kramer for multiple comparisons test and the 
P value is < 0.001, considered extremely significant. 
 
With the transfected cells treated with RLF, the results are compared to the control 
represented in the CRE reporter.  The CRE reporter construct contains a response element 
for the protein kinase A (PKA) signalling pathway, and it is very well established that PKA 
is commonly involved in G-protein coupled receptor signal transduction (Lodish, et al., 
2001).  When transfected cells with the CRE reporter were stimulated by RLF, it triggered 
a cascade of intracellular phosphorylation events.  This ultimately activates the cAMP 
response element binding protein (CREB). This active CREB then binds to the CRE and 
up-regulates the expression of the target gene (Lodish, et al., 2001).  As predicted, the CRE 
reporter which is responsible for the protein kinase A (PKA) pathway showed significant 
readings when induced with rat RLF. In contrast, rat RLF did not display any significant 
change with or without 1% FCS with the NFκB transfected cells, compared to cAMP 
response element (CRE) transfected cells.  However, a slight increase was recorded when 
comparing NFκB against NFκB plus 1% fetal calf serum and stimulated with RLF, but 
considered insignificant by ordinary ANOVA test with parametric standard.  No significant 
value was recorded when comparing NFκB + serum and NFκB + serum stimulated with 
RLF by the same statistical method.  The conclusion to draw here is that RLF has no 
antagonist effect when compared to previous laboratory studies (Fig 4.6).  In addition, the 
results do support the common dogma of RLF having similar mechanisms to other 
members of the G protein receptor super family.   
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In the literature, many signaling pathways have been implicated in the relaxin response, 
but not all have been consistently demonstrated.  In addition, nothing has been reported 
about the effect of RLF on the NFκB signaling pathway.  A study by Halls et al on other 
reporter genes such as CRE, AP1, SRE, NFAT and MYC with RLF and relaxin (Halls, et 
al., 2005), have examined the time course of activation of the five reporters (CRE, AP1, 
SRE, NFAT and MYC) (Halls, et al., 2005).  
 
 Following the treatment with relaxin, the LGR7 receptor produced the greatest SEAP 
response from the CRE reporter gene. The AP1 reporter was also stimulated but to a lesser 
degree than CRE (Halls, et al., 2005).  All other reporter genes tested (SRE, NFAT and 
MYC) produced no response (Halls, et al., 2005).  For the LGR8 receptor treated with 
RLF, the CRE and AP1 reporter genes were also the only reporter genes  tested that 
produced SEAP (Halls, et al., 2005), and that supports the results in this thesis. 
 
As it has been mentioned earlier no studies have been carried out with NFκB reporter and 
RLF therefore this study could be published as a complement to the Halls et al study.  
 
4.4 Future Directions 
Further studies on various transcription factors which are responsive to RLF stimulation or 
inhibition may allow better understanding of the intracellular events involved in 
RLF/LGR8 signaling pathways.  They would also illuminate any cross-talk between 
different pathways. 
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Model 377
Version 3.3
- SemiAdaptive
Version 3.2
26ZN 1 copy RLf TAT/I
z {1
Lane 26
Signal Gr 1 67 A:223 T :255 C:241
DT {BD Set Any-Prime$
Set E Matrix
Points 1 071 to 1 1800 Pk 1 Loc: 1 071
Page 1 ol 2
Man,22 Nov 1999 9:09 AilI
Fri, 19 Nov 1999 2:26 PM
Spacing: 12.25112.251
dllliffiscnEtslfliGesrrrcsr lihcs dtrrMce*acs crccrNrcNrrrcsrcla ccrclBrcteccsrccccccrccccrqcccAcA@ccecGGA€c cccccc rrrccr
10 , 2A -=3{-.----4A:- --E0 --40, 7Q - 80 90 1,00 LL0 rl20
cAccAccr6TGccliDce eccrcc6grgrGCGGTGGcccGccir16TCACCcGAGGccACccAcccr(yrGGAcAccc @GAccsr6A6rGG@AcAcc{GGGcAcA
160 !'70 180 190 200 zLo 220 234 24A
ACGCATGGATAATCAAGTAGGAAGACGCTGGCATIiG?GAC GCC CC CTCC TAATA@AC TC TAAGACTAGAGTC CICATGGAC?T TIAAGTT T'ICCgICTT TT TGGATgTTI GA
250 26A 2'70 280 294 300 310 320 330 340 350
rcAETACCCAGGCT€.EC TCAGACTAACAEIGTA@CATCCAAGAGAACAGTGAAC TGCTTCCTCACTTAGAC??gIGTACTTAGCTGACTGCACGAGC CACC
!74 380 390 400 410 420 430 440 450 460 4'10 480
TTGTTTACTAAACAATACAAGACA GAC TCACTAG@AACCTAAAGTGACT'ICA.XAGrcACAGGAArcCTCCTCC EACCrcCAGTTCTGGGG"ICACTG@?trAT@,CCC TCTTT
490 500 510 520 530 s40 550 550 5'70 580 590
AHA
PRFNT
Model 377
Version 3.3
SemiAdaptive
Version 3.2
27ZN2eapy
anz KIF sroP
Lane27
SignalG:209 A:26'l T:284 C:307
DT {BD Set Any-Primer}
Set E Matrix
Points 1107to 11800 Pk 1 Loc: 1107
Page 1 ol 2
Mon,22 Nov 1999 9:09 AM
Fri,19 Nov 1999 2:26 PM
Spacing: 12.21112.211
ecllhooecerrteecltlflsdheGG r ATsrArA TG cccdGAaaicArracM'rcc.eceecNre ceccacactcccrerctcelEcrcFcAAGccrcercaeeeccr ttlGcre
110 t20
(AGcGc6GsrccscqrcRclGreceArcc di[rcG@cAcGAGcGcGTeAccAGATGrcqrrccrccAcccAcrccAccAGcrcccrgrGcGCAAccAGAAATcAc,crg'Asrcc
130 l_40 - 150 l-50 L1A 180 190 200 zLO 224 234
250 260 2'70 280 290 300 310 320 330 340 350 36(
TGCCTCTCTGCACCCCA TTTqIGG-CATGAAGGqI€AGSTCCCTAGAATTGCAC@A @CTTGGgITTGOCCTG'I13G@CCTTGGATG@AC CC TCTGCTTCS,GGA@EGC
370 380 390 400 4!A 420 430 44A 450 +AO 470
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P a g e  12 l / A 6 / 2 0 0 6  1 2 : 2 5  P M
Repea ted  Measu res  Ana l vs i s  o f  Va r i ance
T h e  P  v a f u e  i s  0 . 0 0 3 1 ,  c o n s i d e r e d  v e r y  s i g n i f i c a n t .
Va r i a t i on  among  co l -umn  means  i s  s i gn i f i can t l y  g rea te r  t han  expec ted
Dy cnance
T r r k e v - K r a m e r  M r r l  I  i  n l  c  C n m n : r i  q o n s  T e S t
I f  t he  va lue  o f  q  i s  s rea te r  t han  3 .877  then  the  P  va ] -ue  i s  f ess
t h a n  0 . 0 5 .
Conparison
Mean
Differenee q P val-ue
N F K b  v s  N F K b  +  S e r u m  - 2 I . 8 I 5  4 . 6 6 1  *  P < 0 . 0 5
N F K b  v s  N F K b  +  S  +  R L F  - 2 9 . 8 0 9  6 . 3 1 7  * *  P < 0 . 0 1
N F K b  +  S e r u m  v s  N F K b  +  S  +  R L F  - 7 . 9 9 3  1 - . 7 1 0  n s  P > 0 . 0 5
Mean 958 Confidence Interval
Difference Difference From To
N F K I :  -  N F K b  +  S e r u m  - 2 I . 8 1 5  - 3 9 . 9 3 8  - 3 . 6 9 3
'  
N F I f t  -  N F K b  +  S  +  R L F  - 2 9 . 8 0 9  - 4 7 . 9 3 r  - 1 1 . 6 8 7
NFKb  +  Se rum -  NFKb  +  S  +  RLF  - ' 7 .993  -26 .115  70 .729
In te rmed ia te  ca lcu f . r t ions .  ANOVA Tab le :
Source of
va r i a t i on
T rea tmen t  (be tween  co lumns )
T n r l  i  r r i  d r r : ' l  i ' h o ] - r ^ r a o n  r n r ^ r q  \
R a n d o m  ( r e s i d u a l )
Degrees  o f  Sum.o f  Mean
f  r a a d n m  e  - r r  a
-a * * res  squa re
2  2 8 5 6  . 1  1 4 2 8  . 4
5  1 1 3 4 - 4  2 2 6 . 8 8
1 0  1 3 1 0 . 9  1 3 1 . 0 9
Tota l - 7 1  5 3 0 2 . 0
F  :  10 .896  :MSt rea tmen t /Ms res idua ]
A c c r r r , n f  i  n n  t -  o < t -  .  W a S  t h e  m a t C h i n c r  e f  f e r : t i  r r c ". ' " " * -
Th f  F  and  a  d i f f e ren t  P  va fue .
F  :  1 .731  : (Ms ind i v i dua " l - lMSres idua l )
The  P  va lue  i s  0 .  2152 ,  cons ide red  no t  s i gn i f i can t .
E f fec t i ve  ma tch j -ng  (o r  b lock ing )  resu l t s  i n  s i gn i f i can t  va r i a t j - on  among
means .  W i th  t hese  da ta ,  t he  ma tch ing  appea rs  no t  t o  be  e f f ec t i ve .
Ordinary ANOVA may be more appropr iate.
Summarv of Data
Nuober Standard
of Standard Eror of
Group Points ' Mean Deviation Mean Median
N F I { o  6  2 2 . 9 8 3  8 . 4 0 2  3 . 4 3 0  2 2 . 1 3 1
N F K b  +  S e r u m  5  4 4 - 1 9 8  3 . 0 4 8  \ . 2 4 4  4 5 . 2 5 1
N F K b  +  S  +  R L F  6  5 2 . 7 9 1  2 0 . 2 2 8  8 . 2 5 8  4 2 . 0 9 0
2 I / 0 6 / 2 0 0 6  L 2 : 2 5  P M D a a o  2
Group
NFKb
NFKb +  Serum
N F K b + S + R L F
Minimum
1 3 . 6 9 0
4 0  . 9 4 6
3 1 . 5 5 2
l'laxi-mum
3 3 . 7 8 8
4 8 . 2 4 3
8 1  .  5 1 6
958 Confidence fnterval
Frorn To
1 4 . 1 6 3  3 L . 8 0 2
4 r . 5 9 9  4 1 . 9 9 1
3 1 . 5 6 0  1 4 . 4 2 3
6 / 2 0 / 2 C 0 6  2 : L 4  P M P :  r r a  1
R c n c a t o d  M e e s r r r e q  A n :  I  r ; s i  s  o f  V a r i a n c e
T h e  P  v a f u e  i s  <  0 . 0 0 0 1 ,  c o n s i d e r e d  e x t r e m e f y  s i g n i f i c a n t .
Va r i a t i on  among  co fumn  means  i s  s i g r , i f i can t l y  g rea te r  t han  expec ted
oy  cnance .
Tukey-Kramer Mul t ip fe Compar isons Test
I f  t he  va fue  o f  q  i s  s rea te r  t han  4 .886  then  the  P  va lue  i s  l ess
t h a n  0 . 0 5 .
Comparison
Cre vs Cre + RLF
Cre vs NFKb
Mean
=:::: "-==L
- 8 4 1 . 4 3  2 3 " 0 ] - 6  * * *  P < 0 . 0 0 1
9 1 . 1 6 9  2 . 6 5 5  n s  P > 0 . 0 5
C r e  v s  N F K b  +  S e r u m  ' 7  4 . 9 5 1  2 . 0 3 6  n s  P > 0 . 0 5
C i e  v s  N F i < b  +  S  +  R L F  6 8 . 2 9 4  1 . 8 5 5  n s  P > 0 . 0 5
Cre + RLF vs NFKb 9 4 5 . 2 0  2 5 . 6 ' 7 1 ,  * * *  P < 0 . 0 0 1
C r e  +  R L F  v s  N F K b  +  S e r u m  9 2 2 - 3 8  2 5 . O 5 I  * * *  P < 0 . 0 0 1
C r e  +  R L F  v s  N F K b  +  S  +  R L F  9 7 5 - 1 2  2 4 . 8 7 I  * * *  P < 0 . 0 0 1
NFKb  vs  NFKb  +  Se rum -22 -878  0 .619 '7  ns  P>0 .05
N F K b  v s  N F K b  +  S  +  R L F  - 2 9 . 4 7 4  0 . 8 0 0 5  n s  P > 0 . 0 5
N F K b  +  S e r u m  v s  N F K b  +  S  +  R L F  - 6 . 6 5 7  0 . 1 8 0 8  n s  P > 0 - 0 5
Mean 958 Confidence Interwal
Difference , Differerree Fr6n To
C r e  -  C r e  +  R L F  - 8 4 1 . . 1 3  - ] . 0 2 i  j . 3  - 6 6 7 . 5 3
C r e  -  N F i i c  9 1  . ' 1 6 9 ,  - 8 2  . 1 3 2  2 1 1  . 6 1
C r e  -  N F K b  +  S e r u m  1 4 . 9 5 i  - 1 0 4 . 9 5  2 5 4 . 8 5
C r e  -  N F K b  +  S  +  R L F  6 8 . 2 9 4  - 1 , 1 1 . 6 1  2 4 8 . 1 9
Cre  +  RLF  -  NF I { c  945 .20  165  -30  I I 25 . I
C r e ' *  R L F  -  N F K b  +  S e r u m  9 2 2 . 3 8  1 4 2 - 4 8  7 1 0 2 . 3
C r e  +  R L F  -  N F K b  +  S  +  R L F  9 L 5 . 7 2  ' 7 3 5 . 8 2  1 0 9 5 . 6
N F K b  -  N F K b  +  S e r u m  - 2 2 - 8 L 8  - 2 4 2 . ' 7 2  1 5 7 . 0 8
N F K b  -  N F K b  +  S  +  R L F  - 2 9 . 4 1 4  - 2 0 9 - 3 8  1 5 0 . 4 3
N F i ( b  +  S e r u m  -  N F K b  +  S  +  R L F  - 6 . 6 5 7  - 1 8 6 . 5 6  L 1 3 . 2 4
In te rmed ia te  ca fcu fa t ions .  ANOVA Tabfe :
Source of
va r i a t i on
Treatment  (between columns)
Ind i v i dua l  ( be tween  rows )
Random ( res idua l - )
Deg_6ees,  of  Sum of  Mean 
.
f r a o r l n m  < d r r l
-a - * res  squa re
4 1"99328 4 498321
2  t 0 9 0 r  5 4 s 0 . 7
B  3 2 5 3 6  4 0 6 1 . 0
T o t a l
F  :  L 2 2 - 5 3  : M S t r e a t m e n t / M S r e s i d u a l -
7 4  2 0 3 6 7 2 2
A s s r m n f i o n  f e s t :  W a s  t h e  m a t c h i n o  e f f e c t i v e ?
Th is  t es t  uses  a  second  va lue  o f  F  and  a  d i f f e ren t  P  va lue .
F  :  1 .  340  : (MS- ind i v i dua l - /MSres idua f  )
6 / 2 0 / 2 0 0 6  2 z 1 4  P M Paqe 2
The  P  va lue  i s  0 .3148 ,  cons ide red  nc r t  s i gn i f i can t .
E f fec t i ve  ma tch ing  (o r  b lock inq )  resu f t s  i n  s i gn i f i can t  va r i a t i on  among
means .  W i th  t hese  da ta ,  t he  ma tch ing  appea rs  no t  t o  be  e f f ec t i ve .
Ord ina ry  ANOVA may  be  more  app rop r i a te .
Summary of Data
Number Standard
of Standard Error of
Group Points Mean Deviation Mean Median
' C r e  3  1 1 9 . 8 7  7 9 . " 7 0 9  1 1 . 3 7 9  1 0 8 . 7 3
C r e  +  R L F  3  9 6 1 . 3 0  7 4 4 . 2 0  8 3 . 2 5 4  L 0 2 8 . 2
N F K b  3  2 2 . 7 0 L  9 . 0 7 2  5 . 2 4 3  2 1 . 0 0 0
N F K b  +  S e r u m  3  4 4 . 9 1 , 9  3 1 8 0  2 . 0 0 9  4 6 - 3 8 2
N F K b  +  S  +  R L F  3  5 1 . 5 7 6  2 I . 0 6 2  1 2 . 7 6 0  4 1 . 2 2 1
95* Confidence Interval
Group Minimum I'laxinum From To
C r e  7 0 8  - 2 6  7 4 2  -  6 3  7 0 .  9 0 5  1 6 8  .  8 3
C r e  +  R L F  8 0 2 . 6 4  1 0 7 1 . 0  6 0 9 . 0 6  I 3 2 a . 5
N F K b  1 3 .  6 9 0  3 1  .  6 1 3  - O  . 2 8 1 3  4 4 . :  4 3 9
N F K b  +  S e r u m  4 0 . 9 4 6  4 1  - 4 2 9  3 6 - 2 1 3  5 3 . 5 d 4
N r K b  +  s  +  R L F  3 ' l  . 6 8 9  7 5 - 8 1 0  - 0 . 7 5 0 7  1 [ ) i . 9 0
* t < *
2 l / 0 6 / 2 0 0 6  3 : 2 5  P M D r a a  1
Repea ted  Measu res  Ana l ys i s  o f  Va r i ance
T h e  P  v a l u e  i s  <  0 . 0 0 0 1 ,  c o n s i - d e r e d  e x t r e m e l y  s i g n i f i c a n t .
Va r i a t i on  among  co lumn  means  i s  s i gn i f i can t l y  g rea te r  t ha r r  expec ted
b y  c h a n c e .
T r r k c r z - K r : m c r  M r r l  f  i n l  e  C o m n a r i  s o n S  T e S tr  s J l v  y  . r ! u r r l v !  ! r s !  u ! v + v  v v f r r v q ! ! r v r r
I f  t he  va lue  o f  q  i s  g rea te r  t han  4 .232  then  the  P  va . l - ue  i s  l ess
t h a n  0 . 0 5 .
Comparison
Mean
Difference q P val-ue
C r e  v s  C r e  +  R L F  - 8 4 6 . 5 2  2 0 . 0 5 7  * * *  P < 0 . 0 0 1
C r e  v s  N F K b  1 0 1 . 1 3  2 . 3 9 6  n s  p > 0 . 0 5
C r e  v s  N F K b  +  S e r u m  7 9 . 3 1 L  1 . 8 7 9  n s  P > O .  0 5
C i e  v s  N F K b  +  S  +  R L F  7 1 . 3 1 8  1 . 6 9 0  n s  P > 0 . 0 5
C r e  +  R L F  v s  N F K b  9 4 1 . 6 5  2 2 . 4 5 3  * * *  P < 0 . 0 0 1
C r e  +  R L F  v s  N F K b  +  S e r u m  9 2 5 . 8 3  2 1 . 9 3 6  * * *  p < 0 . 0 0 1
C r e  *  R L F  v s  N F K b  +  S  +  R L F  9 7 1 . 8 4  2 I . 1 4 6  * * *  p < 0 . 0 0 1
N F K b  v s  N F K b  +  S e r u m  - 2 1 , . 8 1 5  0 . 5 1 6 9  n s  p > 0 . 0 5
N F K b  v s  N F K b  +  S  +  R L F  - 2 9 , 8 0 9  0 . 7 0 6 3  n s  p > 0 . 0 5 "
N F K b  +  S e r u m  v s  N F K b  +  S  +  R L F  - 7 . 9 9 3  0 . 1 8 9 4  n s  p > 0 . 0 5
C r e - C r e + R L F
Cre - NFKb
C r e - N F K b + S e r u m
C r e + R L F - N F K b
C r e + R L F - N F K b + S e r u m
Mean 95t Confidence Interval
Difference From To
- u 4 b .  5 2  - 1 0 2 5 . I  - 6 6 7  . 9 7
1 0 1 . 1 3 - - 7 1 . 4 9 2  2 1 9 . 1 4
7 9 . 3 7 I  - 9 9 . 3 0 7  2 5 7 . 9 3
9 4 7 . 6 5  7 6 9 . 0 3  1 L 2 6 . 3
9 2 5 . 8 3  1  4 7  . 2 2  1 1 0 4  . 5
Difference
C r e  -  N F K b  +  S  +  R L F  7 1 . 3 1 8  - 1 0 7 . 3 0  2 4 9 . 9 4
C r e  +  R L F  -  N F K b  +  S  +  R L F  9 1 1 . 8 4  1 3 9 . 2 2  1 0 9 6 . 5
N F K b  -  N F h a b  +  S e r u m  - 2 I . 8 1 5  - 2 0 0 . 4 3  1 5 6 . 8 0
N F K b  -  N F K b  +  S  +  R L F  - 2 g . 8 } g  - 2 0 8 . 4 3  1 4 8 . 8 1
N F K b  +  S e r u m  -  N F K b  +  S  +  R L F  - 1 . 9 9 3  - 1 8 6 . 6 1  I i 0 . 6 2
In te rmed ia te  ca l cu la t i ons .  ANOVA Tab le :
Sou rce  o f
va r i a t i on
T r F : f  m c n l -  t h o t u r e o n  n n  l  r r m n <  \
v v 4 s r r l r r u  /
f nd i v i dua l  ( be tween  rows )
R : n d o m  l r c q i d r r : l \
\ - v v + s s s ! /
Deqrees  o f  Sum o f  Mean
rreeoom squares square
4  4 0 0 4 7 3 2  1 0 0 1 1 8 3
5  6 5 0 6 8  1 3 0 1 4
2 0  2 1 3 1  6 1  1 0 6 8 8
,  F  :  93 .670  :MSt rea tmen t , /Ms res idua l -
29  4283567
Assumpt ion  te . s t :  Was  the  ma tch inq  e f f ec t i ve?
Th is  t es t  uses  a  second  va l -ue  o f  F  and  a  d i - f f e ren t  p  va fue .
F  :  1 .218  : lUS ind i v i dua l_ /MSr .es idua l_ )
2 ! / 0 6 / 2 0 0 6  3 : 2 5  P M
T h e  P  v a l - u e  i s  0 . 3 3 ' 7 2 ,  c o n s i d e r e d  n o t  s i g n i f i c a n t .
E f fec t i ve  ma tch ing  (o r  b lock ing )  resu l - t s  i n  s i gn i f i can t
means .  W i th  t hese  da ta ,  t he  ma tch ing  appea rs  no t  t o  be
Ordinary ANOVA may be more appropr iate.
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. . - - l  ^ ! . 1  ^ -  - - ^ - ^
v q l f  a !  ! v L ]  o t t r v l t g
e f  f ec t i - r r e .
Summarv of  Data
Group
Cre + RLF
Nl E TaL
NFKb + Serum
N T E . I . l . \  +  Q  +  D T E "
Group
Cre
Cre + RLF
NFKb
NFKb + Serum
N F K b + S + R L F
Nuuber
of
Points
6
O
6
o
6
Mean
1 2 4 . I I
9 7 0 .  6 3
2 2  . 9 8 3
4 4  . 7  9 8
5 2  . 1 9 L
r 5 4  . 6 1
1 2 5 1  . 3
3 3 . 7 8 8
4 8 . 2 4 3
8 1 . 5 1 6
1 9  . 6 1 9
2 3 4 . 2 9
8  . 4 0 2
3 . 0 4 8
2 0 . 2 2 8
Standard
Deviation
Standard
Error of
Mean
8 . 0 0 9
9 s . 6 5 0
3 . 4 3 0
r . 2 4 4
8 . 2 5 8
Median
1 1 5 . 1 9
1 0 4 8 . 8
22 . r31
4 5  . 2 5 1
4 2  . 0 9 0
95t Confidence Interval-
Minimun Maxinum From lo
I O B , 2 6
5 9 5 . 2 5
r - 3 .690
4 0 . 9 4 6
3 1  . 5 5 2
1 0 3 . 5 2
1 2 4  . 7  2
1 4 . 1 6 3
4 I  . 5 9 9
3 1 .  s 6 0
r 4 4  . 7  0
t276 .5
3 1 . 8 0 2
A 1  0 0 1
1  4  . 0 2 3
